[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 36694
1. Winick N: Is immunization necessary after therapy for acute lymphoblastic leukemia (ALL) has been completed? Pediatr Blood Cancer; 2009 Dec;53(6):922-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is immunization necessary after therapy for acute lymphoblastic leukemia (ALL) has been completed?
  • [MeSH-major] Immunization. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


2. Kroll ME, Draper GJ, Stiller CA, Murphy MF: Childhood leukemia incidence in Britain, 1974-2000: time trends and possible relation to influenza epidemics. J Natl Cancer Inst; 2006 Mar 15;98(6):417-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leukemia incidence in Britain, 1974-2000: time trends and possible relation to influenza epidemics.
  • Time trends in incidence of disease may cast light on etiology.
  • We investigated time trends in childhood leukemia by using Poisson regression methods to analyze data from the National Registry of Childhood Tumours, a long-standing high-quality registry that covers the whole childhood population of Britain.
  • During 1974-2000, the average annual percentage change in rate (AAC) of childhood acute lymphoblastic leukemia (ALL) in Britain was 0.7% (95% confidence interval [CI] = 0.4 to 1.0).
  • This increase was apparently driven by the "common" subtype (expressing the CD10 antigen) of precursor B-cell ALL, for which the estimated AAC during 1980-1996 was 1.4% (95% CI = 0.8 to 2.0).
  • There was no statistically significant time trend in other subtypes of ALL combined (1980-1996) or in acute myeloid leukemia (1974-2000).
  • These results are consistent with hypotheses that some childhood leukemia may be triggered by infection occurring close to the time of diagnosis of leukemia, particularly in conditions of low herd immunity, and raise the possibility that contact with influenza shortly before the diagnosis of leukemia may sometimes be involved.
  • [MeSH-major] Disease Outbreaks. Influenza, Human / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology
  • [MeSH-minor] Adolescent. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / virology. Child. Female. Great Britain / epidemiology. Humans. Incidence. Male. Poisson Distribution. Registries

  • MedlinePlus Health Information. consumer health - Flu.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2006 Dec 6;98(23):1746; author reply 1746-7 [17148778.001]
  • (PMID = 16537835.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Szmyd K, Chaber R, Fiszer-Maliszewska L, Reich A, Grotthus E, Weclawek-Tompol J, Chybicka A: [Mean level of expression of c-myb gene in leukaemia of children]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):587-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mean level of expression of c-myb gene in leukaemia of children].
  • AIM OF THE STUDY: Measurement of c-myb expression in leukaemia cells in children and in normal cells of healthy controls.
  • MATERIAL AND METHODS: 37 patients, 23 boys and 14 girls with acute leukaemia, aged 1-17 years, were included in the study (32 with acute lymphoblastic leukaemia and 5 with acute myeloblasts leukaemia) Control group consisted of 17 healthy children, 8 boys and 9 girls, 4-18 years old.
  • RESULTS: Mean level of expression of c-myb gene in leukaemia cells was statistically significantly higher than in the control group (0.71+/-0.53 vs. 0.51+/-0.22; p=0.05), as well as c-myb level between leukaemia cells in relapse cases and controls (0.83+/-0.23 vs. 0.51+/-0.22; p=0.01).
  • There was no difference between c-myb expression in different diagnosis.
  • CONCLUSIONS: Possible influence of increased expression of c-myb gene in the promotion of leukaemia was found.
  • The role of c-myb expression as a prognostic factor in acute leukaemias of children was not confirmed.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-myb / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317889.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myb
  •  go-up   go-down


Advertisement
4. Drake-Lee A: Left-right discrimination. It's all about coordination and laterality. BMJ; 2009;338:b34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left-right discrimination. It's all about coordination and laterality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] BMJ. 2008;337:a2906 [19088147.001]
  • (PMID = 19136539.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


5. Salisbury DM: (Not) warts and all. Government fully considered HPV vaccine. BMJ; 2008;337:a2552
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (Not) warts and all. Government fully considered HPV vaccine.
  • [MeSH-major] Condylomata Acuminata / prevention & control. Papillomavirus Vaccines
  • [MeSH-minor] Cost-Benefit Analysis. Government Programs. Great Britain. Humans

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] BMJ. 2008;337:a2186 [18948345.001]
  • (PMID = 19019858.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  •  go-up   go-down


6. Jaime-Pérez JC, González-Llano O, Herrera-Garza JL, Gutiérrez-Aguirre H, Vázquez-Garza E, Gómez-Almaguer D: Assessment of nutritional status in children with acute lymphoblastic leukemia in Northern México: A 5-year experience. Pediatr Blood Cancer; 2008 Feb;50(2 Suppl):506-8; discussion 517
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of nutritional status in children with acute lymphoblastic leukemia in Northern México: A 5-year experience.
  • Nutritional status is an important variable when planning the treatment of children with acute lymphoblastic leukemia (ALL).
  • The majority of children with ALL in Northern Mexico are well nourished at diagnosis and have a normal body composition.
  • [MeSH-major] Nutrition Assessment. Nutritional Status. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18064642.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


7. Bakhshi S, Sethuraman G, Singh MK, Arya LS: Atypical pyoderma gangrenosum as a manifestation of childhood acute lymphoblastic leukemia. Pediatr Dermatol; 2005 Nov-Dec;22(6):543-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical pyoderma gangrenosum as a manifestation of childhood acute lymphoblastic leukemia.
  • Although the association of this entity with myeloid malignancies is well known, its association with lymphoid malignancy is extremely rare.
  • We describe atypical pyoderma gangrenosum in association with acute lymphoblastic leukemia in a 2-year-old child, an occurrence not reported before.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyoderma Gangrenosum / drug therapy. Pyoderma Gangrenosum / pathology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Asparaginase / therapeutic use. Biopsy, Needle. Child, Preschool. Daunorubicin / therapeutic use. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Male. Prednisone / therapeutic use. Risk Assessment. Severity of Illness Index. Treatment Outcome. Vincristine / therapeutic use


8. Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A, Maertens J, Slavin S, Majolino I, Nagler A, Blaise D, Rocha V, Acute Leukemia Working Party, European Group for Blood and Marrow Transplantation: Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica; 2008 Feb;93(2):303-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.
  • This retrospective study reported the outcome of 97 adult acute lymphoblastic leukemia patients who received a reduced-intensity conditioning allogeneic stem cell transplantation.
  • With a median follow-up of 2.8 years, two year overall-survival, leukemia-free survival and non-relapse mortality were significantly better in patients transplanted in first complete remission (CR1, 52+/-9%; 42+/-10%; and 18+/-7% respectively) compared with those transplanted in more advanced phase (p=0.003, p=0.002 and p=0.01 respectively).
  • In multivariate analysis, disease status (CR1 vs. advanced; p=0.001) and chronic graft-vs-host disease (p=0.01) were associated with an improved overall-survival, suggesting that reduced-intensity conditioning allogeneic stem cell transplantation is feasible in patients with high risk lymphoblastic leukemia in remission at transplantation.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Aged. Chronic Disease. Disease-Free Survival. Europe. Female. Follow-Up Studies. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Homologous


9. Buendia MT, Lozano JM, Suarez GE, Saavedra C, Guevara G: The impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombia. J Pediatr Hematol Oncol; 2008 Sep;30(9):643-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombia.
  • To improve the outcome of children with acute lymphoblastic leukemia (ALL) treated at the National Cancer Institute, Bogota, Colombia, a protocol based on the BFM-90 (Berlin, Frankfurt, Munster study) and the LSA2L2 regimens was implemented in the year 1993.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Central Nervous System Neoplasms / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18776755.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] VB0R961HZT / Prednisone
  •  go-up   go-down


10. Santoro A, Cannella S, Trizzino A, Lo Nigro L, Corsello G, Aricò M: A single amino acid change A91V in perforin: a novel, frequent predisposing factor to childhood acute lymphoblastic leukemia? Haematologica; 2005 May;90(5):697-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single amino acid change A91V in perforin: a novel, frequent predisposing factor to childhood acute lymphoblastic leukemia?
  • We screened 100 children with acute lymphoblastic leukemia (ALL) to assess the incidence of single amino acid change A91V in perforin.
  • [MeSH-major] Amino Acid Substitution. Membrane Glycoproteins / genetics. Mutation, Missense. Pore Forming Cytotoxic Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. DNA Mutational Analysis. DNA, Neoplasm / genetics. Female. Genetic Predisposition to Disease. Genetic Testing. Genotype. Humans. Incidence. Infant. Infant, Newborn. Lymphohistiocytosis, Hemophagocytic / genetics. Male. Perforin. Polymorphism, Single Nucleotide

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921391.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Membrane Glycoproteins; 0 / Pore Forming Cytotoxic Proteins; 126465-35-8 / Perforin
  •  go-up   go-down


11. Steffens M, Beauloye V, Brichard B, Robert A, Alexopoulou O, Vermylen Ch, Maiter D: Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). Clin Endocrinol (Oxf); 2008 Nov;69(5):819-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL).
  • BACKGROUND: Treatments of acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma (NHL), involving various combinations of chemotherapy (chemo), cranial irradiation (CI) and/or bone marrow transplantation after total body irradiation (BMT/TBI), are often successful but may have several long-term harmful effects.
  • [MeSH-major] Endocrine System Diseases / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Metabolic Diseases / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Survivors / statistics & numerical data


12. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med; 2006 Jun 15;354(24):2542-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML).
  • METHODS: In a phase 1 dose-escalation study, we assigned 119 patients with imatinib-resistant CML or acute lymphoblastic leukemia (ALL) to receive nilotinib orally at doses of 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, and 1200 mg once daily and at 400 mg and 600 mg twice daily.
  • Of 33 patients with the blastic phase of disease, 13 had a hematologic response and 9 had a cytogenetic response; of 46 patients with the accelerated phase, 33 had a hematologic response and 22 had a cytogenetic response; 11 of 12 patients with the chronic phase had a complete hematologic remission.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Fusion Proteins, bcr-abl / antagonists & inhibitors. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Protein Kinase Inhibitors / administration & dosage. Pyrimidines / administration & dosage

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Massachusetts Medical Society.
  • [CommentIn] N Engl J Med. 2006 Jun 15;354(24):2594-6 [16775240.001]
  • (PMID = 16775235.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00109707
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / abl-bcr fusion protein, human; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


13. Foster M: Sports dentistry--what's it all about? SADJ; 2009 Jun;64(5):198, 200-2, 204 passim
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CLINICAL RELEVANCE: The early diagnosis and management of dental conditions that affect athletes will ensure sound dental health is preserved for these high risk patients.
  • The clinician needs to be aware of a variety of dental conditions that can prevent significant dental trauma and acute manifestations at the time of competition.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintOf] Dent Update. 2009 Apr;36(3):135-8, 141-4 [19480101.001]
  • (PMID = 19725331.001).
  • [ISSN] 1029-4864
  • [Journal-full-title] SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging
  • [ISO-abbreviation] SADJ
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  •  go-up   go-down


14. Conklin HM, Lawford J, Jasper BW, Morris EB, Howard SC, Ogg SW, Wu S, Xiong X, Khan RB: Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial. Pediatrics; 2009 Jul;124(1):226-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate the frequency and severity of side effects of methylphenidate among childhood survivors of acute lymphoblastic leukemia and brain tumors and identify predictors of higher adverse effect levels.
  • [MeSH-major] Brain Neoplasms / epidemiology. Central Nervous System Stimulants / adverse effects. Cognition Disorders / drug therapy. Cognition Disorders / epidemiology. Methylphenidate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurol. 2002 Apr;26(4):261-6 [11992752.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1802-8 [11251012.001]
  • [Cites] Pediatr Rehabil. 2004 Jan-Mar;7(1):1-14; discussion 15-6 [14744668.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2004 May;43(5):559-67 [15100562.001]
  • [Cites] J Child Psychol Psychiatry. 1977 Apr;18(2):137-65 [326801.001]
  • [Cites] Pediatrics. 1990 Aug;86(2):184-92 [2196520.001]
  • [Cites] J Child Psychol Psychiatry. 1992 Jan;33(1):153-95 [1371122.001]
  • [Cites] J Child Neurol. 1992 Oct;7(4):462-3 [1469256.001]
  • [Cites] Pediatrics. 1993 Jun;91(6):1101-6 [8502509.001]
  • [Cites] Child Psychiatry Hum Dev. 1993 Fall;24(1):25-30 [8404241.001]
  • [Cites] J Clin Exp Neuropsychol. 1994 Feb;16(1):21-42 [8150888.001]
  • [Cites] Pediatrics. 1997 Oct;100(4):662-6 [9310521.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4795-803 [15570081.001]
  • [Cites] Ann Pharmacother. 2006 Jun;40(6):1134-42 [16735655.001]
  • [Cites] Drug Saf. 2007;30(1):17-26 [17194168.001]
  • [Cites] Expert Rev Neurother. 2007 Feb;7(2):195-201 [17286552.001]
  • [Cites] J Pediatr Psychol. 2007 Oct;32(9):1127-39 [17569711.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Apr;22(2):211-31, v-vi [18395146.001]
  • [Cites] J Consult Clin Psychol. 2008 Jun;76(3):367-78 [18540731.001]
  • [Cites] Clin Psychol Rev. 2002 Nov;22(8):1107-31 [12436807.001]
  • (PMID = 19564304.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00576472
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078957-05; United States / NCI NIH HHS / CA / P30 CA021765-30; United States / NCI NIH HHS / CA / P30CA21765; United States / NCI NIH HHS / CA / R01 CA078957; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / U01 CA081445-05; United States / NCI NIH HHS / CA / R01CA078957; United States / NCI NIH HHS / CA / U01 CA81445
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate
  • [Other-IDs] NLM/ NIHMS78776; NLM/ PMC2705008
  •  go-up   go-down


15. Griffioen M, Kessler JH, Borghi M, van Soest RA, van der Minne CE, Nouta J, van der Burg SH, Medema JP, Schrier PI, Falkenburg JH, Osanto S, Melief CJ: Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res; 2006 May 15;12(10):3130-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
  • PURPOSE: Preferentially expressed antigen on melanomas (PRAME) is an interesting antigen for T-cell therapy because it is frequently expressed in melanomas (95%) and other tumor types.
  • Moreover, due to its role in oncogenic transformation, PRAME-negative tumor cells are not expected to easily arise and escape from T-cell immunity.
  • The purpose of this study is to investigate the usefulness of PRAME as target for anticancer T-cell therapies.
  • EXPERIMENTAL DESIGN: HLA-A*0201-subtyped healthy individuals and advanced melanoma patients were screened for CD8+ T cells directed against previously identified HLA-A*0201-binding PRAME peptides by IFN-gamma enzyme-linked immunosorbent spot assays and tetramer staining.
  • PRAME-specific T-cell clones were isolated and tested for recognition of melanoma and acute lymphoid leukemia (ALL) cell lines.
  • PRA(100-108)-tetramer+ T-cell clones were shown to recognize and lyse HLA-A*0201+ and PRAME+ melanoma but not ALL cell lines.
  • Quantitative real-time reverse transcription-PCR showed significantly lower PRAME mRNA levels in ALL than in melanoma cell lines, suggesting that PRAME expression in ALL is below the recognition threshold of our PRA(100-108)-tetramer+ T cells.
  • CONCLUSION: These data support the usefulness of PRAME and in particular the PRA(100-108) epitope as target for T-cell therapy of PRAME-overexpressing cancers.
  • [MeSH-minor] Enzyme-Linked Immunosorbent Assay. Epitopes. HLA-A Antigens / immunology. HLA-A2 Antigen. Humans. Immunotherapy / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707612.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Epitopes; 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / PRAME protein, human
  •  go-up   go-down


16. Thomas DA, O'Brien S, Cortes J, Kantarjian H: New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia. Curr Hematol Malig Rep; 2007 Jul;2(3):183-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia.
  • The discovery of targeted ABL tyrosine kinase inhibitors has allowed significant advances in the treatment of de novo Philadelphia chromosome (Ph)-positive ALL.
  • Whereas the outcome with standard chemotherapy was previously dismal, the use of imatinib in front-line therapy has improved relapse-free survival and overall survival, even in the absence of allogeneic stem cell transplantation in first complete remission (particularly for those with comorbidities or lack of a suitable donor).
  • Optimal use of these novel agents in the treatment schema of Ph-positive ALL will be paramount in ensuring continued success in the eradication of this disease.
  • [MeSH-major] Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzamides. Clinical Trials as Topic / statistics & numerical data. Combined Modality Therapy. Disease-Free Survival. Drug Delivery Systems. Drug Resistance, Neoplasm / genetics. Fusion Proteins, bcr-abl / antagonists & inhibitors. Fusion Proteins, bcr-abl / genetics. Humans. Imatinib Mesylate. Multicenter Studies as Topic / statistics & numerical data. Recurrence. Remission Induction. Stem Cell Transplantation. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2531-41 [16775234.001]
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):263-73 [10674898.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4603-11 [8541551.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):481-7 [12181402.001]
  • [Cites] Blood. 2003 Jan 15;101(2):690-8 [12509383.001]
  • [Cites] Blood. 1995 Jul 15;86(2):726-36 [7606002.001]
  • [Cites] Blood. 2007 May 1;109(9):3676-8 [17213285.001]
  • [Cites] Science. 1990 Feb 16;247(4944):824-30 [2406902.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4674-81 [14581336.001]
  • [Cites] Blood. 2005 Jul 15;106(2):458-63 [15817679.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3353-4 [7756668.001]
  • [Cites] J Immunol. 1997 Nov 15;159(10):4720-8 [9366395.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):129-41 [15710326.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4500-5 [15930265.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2532-9 [15256422.001]
  • [Cites] Semin Hematol. 2006 Apr;43(2):126-33 [16616046.001]
  • [Cites] Blood. 1992 Jun 1;79(11):3067-70 [1586748.001]
  • [Cites] Blood. 2005 May 1;105(9):3449-57 [15657178.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2190-6 [12399961.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):623-32 [12692601.001]
  • [Cites] Science. 2000 Sep 15;289(5486):1938-42 [10988075.001]
  • [Cites] J Biol Chem. 1996 Dec 6;271(49):31704-10 [8940193.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1079-82 [2408149.001]
  • [Cites] Science. 2004 Jul 16;305(5682):399-401 [15256671.001]
  • [Cites] Nature. 1990 Mar 15;344(6263):251-3 [2179728.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6987-93 [16203792.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2791-3 [17119111.001]
  • [Cites] Cancer. 2007 May 15;109(10):2068-76 [17429836.001]
  • [Cites] Leukemia. 2005 Apr;19(4):628-35 [15744351.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Blood. 2007 Jan 15;109(2):500-2 [16990603.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Dec;10(12):883-4 [15570257.001]
  • [Cites] Blood. 2007 Jul 15;110(2):727-34 [17405907.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1526-32 [16838024.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Cell. 2003 Mar 21;112(6):831-43 [12654249.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3739-45 [15315971.001]
  • [Cites] Int J Oncol. 1998 Jun;12 (6):1269-76 [9592185.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):695-8 [15160941.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):21-36 [11258387.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3948-54 [16105974.001]
  • [Cites] Nature. 1973 Jun 1;243(5405):290-3 [4126434.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2357-66 [12239143.001]
  • [Cites] Science. 2001 Aug 3;293(5531):876-80 [11423618.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):117-25 [12204532.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2542-51 [16775235.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Blood. 1998 Jun 1;91(11):3995-4019 [9596644.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] Blood. 2003 Jul 15;102(2):659-61 [12663457.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1421-3 [16601247.001]
  • (PMID = 20425368.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 59
  •  go-up   go-down


17. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, Larson RA, Nachman J, Children's Cancer Group, Cancer and Leukemia Group B studies: What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood; 2008 Sep 1;112(5):1646-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.
  • We performed a retrospective comparison of presenting features, planned treatment, complete remission (CR) rate, and outcome of 321 adolescents and young adults (AYAs) ages 16 to 20 years with newly diagnosed acute lymphoblastic leukemia (ALL) who were treated on consecutive trials in either the Children's Cancer Group (CCG) or the Cancer and Leukemia Group B (CALGB) from 1988 to 2001.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2222-30 [9196134.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Leukemia. 1998 Apr;12(4):463-73 [9557602.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1556-64 [9716583.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2032-5 [15483674.001]
  • [Cites] Eur J Haematol. 2005 Jun;74(6):466-80 [15876250.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):734-45 [15952999.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):166-73 [16029445.001]
  • [Cites] Dan Med Bull. 2006 Feb;53(1):76-9 [16761337.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1551-61 [16955505.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:128-32 [17124051.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):254-61 [16421910.001]
  • [Cites] Blood. 2007 May 15;109(10):4164-7 [17264295.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):760-1 [12610169.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1471-80 [12627512.001]
  • [Cites] Blood. 2003 May 15;101(10):3809-17 [12531809.001]
  • [Cites] Leukemia. 1998 Feb;12(2):144-9 [9519775.001]
  • [Cites] Cancer Treat Rev. 2004 Feb;30(1):37-51 [14766125.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S127-8 [15124704.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Med Pediatr Oncol. 1990;18(4):273-9 [2355886.001]
  • [Cites] Cancer. 1991 Aug 15;68(4):751-8 [1855175.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [CommentIn] Blood. 2009 Feb 19;113(8):1861; author reply 1862 [19228933.001]
  • (PMID = 18502832.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA 31946; United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2518876
  •  go-up   go-down


18. Roncador G, García Verdes-Montenegro JF, Tedoldi S, Paterson JC, Klapper W, Ballabio E, Maestre L, Pileri S, Hansmann ML, Piris MA, Mason DY, Marafioti T: Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica; 2007 Aug;92(8):1059-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma.
  • BACKGROUND AND OBJECTIVES: In the present paper we report that SAP, an intracytoplasmic molecule that is involved in cell signaling, is an immunohistologic marker for germinal center T cells in paraffin-embedded tissue.
  • We document its expression, and also that of PD-1 (another recently described marker of germinal center T cells to which a new antibody has been raised), in normal and neoplastic lymphoid tissue to evaluate the suggestion that helper T cells within the germinal centers of human lymphoid tissue are the cell of origin of angioimmunoblastic T-cell lymphoma (AITL), and to assess the diagnostic value of these two markers.
  • DESIGN AND METHODS: Expression of SAP and PD-1 was investigated by immunohistochemistry in paraffin-embedded tissue sections and in cell lines.
  • Western blotting was performed on cell lines, and antibody specificity was confirmed by immunostaining of transfected cells.
  • RESULTS Screening on more than 500 lymphoma biopsies showed that 95% (40/42) of cases of AITL expressed at least one of these markers.
  • SAP was also expressed on many cases (15/21) of acute T lymphoblastic leukemia, in keeping with its presence in cortical thymocytes.
  • However, PD-1 and SAP were also found in a minority of cases of peripheral T-cell lymphoma other than AITL, in contrast to a report that the former marker is specific for AITL.
  • They may also prove of value in the diagnosis of this disease since a negative reaction was rarely observed in this disorder.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Antigens, CD / analysis. Antigens, Differentiation, T-Lymphocyte / analysis. Apoptosis Regulatory Proteins / analysis. Germinal Center / pathology. Immunoblastic Lymphadenopathy / pathology. Intracellular Signaling Peptides and Proteins / analysis. Lymphoma, T-Cell / pathology. Neoplasm Proteins / analysis. T-Lymphocytes / chemistry
  • [MeSH-minor] Hodgkin Disease / metabolism. Hodgkin Disease / pathology. Humans. Lymphocytes, Tumor-Infiltrating / chemistry. Lymphocytes, Tumor-Infiltrating / pathology. Lymphoma, B-Cell / chemistry. Lymphoma, B-Cell / pathology. Palatine Tonsil / pathology. Programmed Cell Death 1 Receptor. Spleen / pathology. Thymus Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640856.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / SH2D1A protein, human
  •  go-up   go-down


19. Heinzelmann F, Ottinger H, Müller CH, Allgaier S, Faul C, Bamberg M, Belka C: Total-body irradiation--role and indications: results from the German Registry for Stem Cell Transplantation (DRST). Strahlenther Onkol; 2006 Apr;182(4):222-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total-body irradiation--role and indications: results from the German Registry for Stem Cell Transplantation (DRST).
  • BACKGROUND AND PURPOSE: Total-body irradiation (TBI) is a key part of the conditioning regimen before hematopoietic stem cell transplantation (HSCT).
  • MATERIAL AND METHODS: 14,371 patients (1998-2002) documented in the German Stem Cell Transplantation Registry (DRST) were analyzed regarding TBI utilization prior to autologous or allogeneic transplantation, underlying disorder, type of donor, stem cell source, and size of the treatment center.
  • RESULTS: For autologous HSCT approximately 10% of the patients (873/8,167) received TBI, with chronic lymphocytic leukemia (CLL, approximately 80%, 171/214) and low-grade non-Hodgkin's lymphoma (l-NHL, approximately 35%, 330/929) being the most important disorders.
  • In the allogeneic setting 50% of the patients (2,399/4,904) received TBI, with acute lymphocytic leukemia (ALL, 85%, 794/930), acute myeloid leukemia (AML, 45%, 662/1,487) and chronic myeloid leukemia (CML, 49%, 561/1,156) being the key indications.
  • The type of donor, stem cell source and center size did not strongly influence the use of TBI.
  • [MeSH-major] Registries. Stem Cell Transplantation. Transplantation Conditioning. Whole-Body Irradiation
  • [MeSH-minor] Acute Disease. Germany. Histocompatibility Testing. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid / therapy. Lymphoma, Non-Hodgkin / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Tissue Donors. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622624.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


20. He YL, Li CF, Shi L: [High dose methotrexate induced acute renal insufficiency in a patient with acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2007 Jan;45(1):78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High dose methotrexate induced acute renal insufficiency in a patient with acute lymphoblastic leukemia].
  • [MeSH-major] Acute Kidney Injury / chemically induced. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349162.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


21. Beesley AH, Firth MJ, Ford J, Weller RE, Freitas JR, Perera KU, Kees UR: Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. Br J Cancer; 2009 Jun 16;100(12):1926-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism.
  • Glucocorticoids (GCs) are among the most important drugs for acute lymphoblastic leukaemia (ALL), yet despite their clinical importance, the exact mechanisms involved in GC cytotoxicity and the development of resistance remain uncertain.
  • We examined the baseline profile of a panel of T-ALL cell lines to determine factors that contribute to GC resistance without prior drug selection.
  • [MeSH-major] Cell Proliferation / drug effects. Dexamethasone / pharmacology. Drug Resistance, Neoplasm. Methylprednisolone / pharmacology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Signal Transduction / drug effects


22. Lv L, Wu C, Sun H, Zhu S, Yang Y, Chen X, Fu H, Bao L: Combined 677CC/1298AC genotypes of methylenetetrahydrofolate reductase (MTHFR ) reduce susceptibility to precursor B lymphoblastic leukemia in a Chinese population. Eur J Haematol; 2010 Jun;84(6):506-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined 677CC/1298AC genotypes of methylenetetrahydrofolate reductase (MTHFR ) reduce susceptibility to precursor B lymphoblastic leukemia in a Chinese population.
  • It has been suggested that two MTHFR polymorphisms, 677C>T and 1298A>C, influence risk of acute lymphoblastic leukemia (ALL).
  • Here, we report a case-control study of 127 Chinese patients with adult precursor B lymphoblastic leukemia (B-ALL) to examine correlation between the MTHFR polymorphisms and B-ALL susceptibility in adults.
  • [MeSH-major] Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Single Nucleotide. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group / genetics. Base Sequence. Case-Control Studies. China. Confidence Intervals. DNA Primers / genetics. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Haplotypes. Humans. Male. Middle Aged. Odds Ratio. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20374270.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


23. Strick R, Zhang Y, Emmanuel N, Strissel PL: Common chromatin structures at breakpoint cluster regions may lead to chromosomal translocations found in chronic and acute leukemias. Hum Genet; 2006 Jun;119(5):479-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common chromatin structures at breakpoint cluster regions may lead to chromosomal translocations found in chronic and acute leukemias.
  • The t(9;22) BCR/ABL fusion is associated with over 90% of chronic myelogenous and 25% of acute lymphocytic leukemia.
  • Chromosome 11q23 translocations in acute myeloid and lymphoid leukemia cells demonstrate myeloid lymphoid leukemia (MLL) fusions with over 40 gene partners, like AF9 and AF4 on chromosomes 9 and 4, respectively.
  • Therapy-related leukemia is associated with the above gene rearrangements following the treatment with topoisomerase II (topo II) inhibitors.
  • In this report, using cell lines and primary cells, chromatin structural elements were analyzed in BCR, ABL and AF4 and, for comparison, in MLL2, which is a homolog to MLL, but not associated with chromosome translocations.
  • Although MLL2 was expressed in all cell lines tested, except for the presence of one DNAse I site in the promoter, no other structural elements were found in MLL2.
  • A NHR model presented demonstrates the importance of chromatin structure in chromosome translocations involved with leukemia.
  • [MeSH-major] Chromatin / chemistry. Chromosome Breakage. Chromosomes, Human / genetics. Leukemia / genetics. Leukemia / metabolism. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Cell Line, Tumor. Cells, Cultured. Chronic Disease. Humans. K562 Cells. Proto-Oncogene Proteins c-bcr / chemistry. Proto-Oncogene Proteins c-bcr / genetics. Recombination, Genetic

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1997 May 20;36(20):5934-9 [9166762.001]
  • [Cites] Cell. 1985 May;41(1):127-32 [2986841.001]
  • [Cites] Gene. 2002 May 29;291(1-2):251-7 [12095698.001]
  • [Cites] EMBO J. 1990 Apr;9(4):1319-27 [2323342.001]
  • [Cites] Science. 1994 Jan 28;263(5146):515-8 [8290959.001]
  • [Cites] Curr Biol. 2000 Jul 27-Aug 10;10(15):923-6 [10959840.001]
  • [Cites] Leukemia. 1996 Feb;10(2):372-7 [8637251.001]
  • [Cites] J Cell Biochem. 2001;82(2):299-309 [11527155.001]
  • [Cites] Genomics. 1995 May 1;27(1):67-82 [7665185.001]
  • [Cites] Annu Rev Biochem. 1989;58:351-75 [2549853.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6236-9 [8016145.001]
  • [Cites] Oncogene. 1989 May;4(5):559-67 [2657572.001]
  • [Cites] Oncogene. 1990 Nov;5(11):1669-73 [2267134.001]
  • [Cites] Oncogene. 2001 May 24;20(23):2900-7 [11420702.001]
  • [Cites] J Cell Biol. 2001 Dec 10;155(6):899-910 [11739403.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Apr;33(4):331-45 [11921269.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4790-5 [10758153.001]
  • [Cites] EMBO J. 2002 Oct 1;21(19):5269-80 [12356743.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Oct;32(2):144-54 [11550282.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Apr;36(4):393-401 [12619163.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(7):2076-80 [2832845.001]
  • [Cites] Nucleic Acids Res. 1997 Feb 1;25(3):511-7 [9016589.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14 ):3357-62 [10416593.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98 (17 ):9802-7 [11493704.001]
  • [Cites] Oncogene. 1998 Dec 3;17(22):2921-31 [9879998.001]
  • [Cites] J Cell Sci. 2004 Sep 1;117(Pt 19):4583-90 [15331666.001]
  • [Cites] Nucleic Acids Res. 1988 Jun 24;16(12):5533-56 [2838820.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(14):5497-501 [2546156.001]
  • [Cites] Cell. 1995 Dec 29;83(7):1137-48 [8548801.001]
  • [Cites] J Cell Biochem Suppl. 2000;Suppl 35:3-22 [11389527.001]
  • [Cites] Hum Mol Genet. 1998 May;7(5):767-76 [9536079.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1671-9 [10861294.001]
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):4973-84 [1656219.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14535-40 [10588740.001]
  • [Cites] Cell Mol Life Sci. 2002 Feb;59(2):373-85 [11915950.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):4070-9 [9199342.001]
  • [Cites] Biochem J. 1994 Nov 1;303 ( Pt 3):681-95 [7980433.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2649-58 [8639880.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10 ):4631-5 [8506309.001]
  • [Cites] Hum Mol Genet. 2002 Jun 1;11(12):1391-7 [12023981.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21458-67 [11940566.001]
  • [Cites] Hum Mutat. 2003 Sep;22(3):229-44 [12938088.001]
  • [Cites] Cell. 1992 Nov 13;71(4):701-8 [1423625.001]
  • [Cites] Oncogene. 1998 Dec 10;17 (23 ):3035-44 [9881706.001]
  • [Cites] Genomics. 1999 Jul 15;59(2):187-92 [10409430.001]
  • [Cites] Leuk Res. 2002 Aug;26(8):713-20 [12191565.001]
  • [Cites] Br J Haematol. 1999 Apr;105(1):256-64 [10233389.001]
  • [Cites] Blood. 2000 Feb 1;95(3):738-43 [10648381.001]
  • [Cites] Oncogene. 1999 Dec 23;18(56):7975-84 [10637508.001]
  • [Cites] Cancer Res. 1995 Jan 1;55(1):34-8 [7805037.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1855-62 [8620504.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1912-22 [8634439.001]
  • [Cites] Nature. 2001 Sep 27;413(6854):435-8 [11574892.001]
  • [Cites] Cancer Lett. 2003 Apr 10;193(1):1-9 [12691817.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1571-4 [9305614.001]
  • [Cites] Chromosoma. 1996 Aug;105(2):122-33 [8753702.001]
  • [Cites] Leukemia. 1999 Dec;13(12):2107-13 [10602437.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4489-92 [8402620.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2986-97 [10082566.001]
  • [Cites] Hum Genet. 2003 Jul;113(1):80-91 [12665971.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3793-803 [9808573.001]
  • [Cites] Genomics. 1998 Jan 15;47(2):217-29 [9479494.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3778-83 [11739186.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3237-42 [11751629.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Sep;35(1):92-6 [12203795.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4550-5 [11389089.001]
  • [Cites] Blood. 1990 Aug 1;76(3):597-601 [2198962.001]
  • [Cites] Genetics. 2002 Apr;160(4):1363-73 [11973293.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9882-7 [12114534.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Nov;41(3):257-65 [15334549.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4411-3 [10781030.001]
  • [Cites] FASEB J. 2004 Jan;18(1):173-5 [14630694.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Apr;33(4):362-78 [11921271.001]
  • [Cites] Mol Pharmacol. 1998 Jul;54(1):78-85 [9658192.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2656-62 [15087374.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3070-5 [11867721.001]
  • [Cites] Semin Hematol. 1999 Oct;36(4 Suppl 7):59-72 [10595755.001]
  • [Cites] Chromosoma. 1991 Feb;100(2):97-102 [1849068.001]
  • [Cites] Leukemia. 1998 Mar;12(3):346-52 [9529129.001]
  • [Cites] Leukemia. 1995 Aug;9(8):1305-12 [7643617.001]
  • (PMID = 16572268.001).
  • [ISSN] 0340-6717
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chromatin; EC 2.7.11.1 / BCR protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  •  go-up   go-down


24. Chong SC, Joo SJ, Emmanouil TA, Treisman A: Statistical processing: not so implausible after all. Percept Psychophys; 2008 Oct;70(7):1327-34; discussion 1335-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statistical processing: not so implausible after all.
  • Myczek and Simons (2008) have shown that findings attributed to a statistical mode of perceptual processing can, instead, be explained by focused attention to samples of just a few items.
  • Some new findings raise questions about this claim. (1) Participants, given conditions that would require different focused attention strategies, did no worse when the conditions were randomly mixed than when they were blocked. (2) Participants were significantly worse at estimating the mean size when given small samples than when given the whole display. (3) One plausible suggested strategy--comparing the largest item in each display, rather than the mean size--was not, in fact, used.
  • Distributed attention to sets of similar stimuli, enabling a statistical-processing mode, provides a coherent account of these and other phenomena.
  • [MeSH-major] Cognition. Data Interpretation, Statistical
  • [MeSH-minor] Humans

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Percept Psychophys. 2008 Jul;70(5):772-88 [18613626.001]
  • (PMID = 18927015.001).
  • [ISSN] 0031-5117
  • [Journal-full-title] Perception & psychophysics
  • [ISO-abbreviation] Percept Psychophys
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / 2R01 MH 058383-04A1
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Pérez-Gómez J, Moore I: Plant endocytosis: it is clathrin after all. Curr Biol; 2007 Mar 20;17(6):R217-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plant endocytosis: it is clathrin after all.
  • Endocytosis occurs in plants, but the involvement of clathrin-coated vesicles has been unclear; a new study provides strong evidence that, as in animal cells, clathrin-coated vesicles are a major means of internalisation by plant cells.
  • [MeSH-major] Arabidopsis / metabolism. Clathrin / physiology. Clathrin-Coated Vesicles / physiology. Endocytosis / physiology
  • [MeSH-minor] Protoplasts / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Curr Biol. 2007 Mar 20;17(6):520-7 [17306539.001]
  • (PMID = 17371763.001).
  • [ISSN] 0960-9822
  • [Journal-full-title] Current biology : CB
  • [ISO-abbreviation] Curr. Biol.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BBS/B/09562
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Clathrin
  •  go-up   go-down


26. Virely C, Moulin S, Cobaleda C, Lasgi C, Alberdi A, Soulier J, Sigaux F, Chan S, Kastner P, Ghysdael J: Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia; 2010 Jun;24(6):1200-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia.
  • [MeSH-major] Fusion Proteins, bcr-abl / physiology. Genes, Tumor Suppressor / physiology. Ikaros Transcription Factor / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


27. Zhu N, Gu L, Li F, Zhou M: Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther; 2008 May;7(5):1101-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells.
  • The phosphatidylinositol 3-kinase (PI3K)/Akt and p53 pathways play antiapoptotic and proapoptotic roles in cell death, respectively.
  • Cancer cell growth and progression are associated with high levels of PI3K/Akt activation by loss of PTEN expression and the inactivation of p53 by MDM2 overexpression.
  • We report that inhibition of PI3K/Akt, either by the PI3K inhibitor Ly294002 or by expression of PTEN, synergized the ability of the MDM2 antagonist nutlin-3 to induce apoptosis in acute lymphoblastic leukemia (ALL).
  • We used a set of ALL cell lines with wild-type p53 and MDM2 overexpression, but different status of PTEN expression/PI3K/Akt activation, to test the ability of nutlin-3 to induce p53 and apoptosis.
  • Nutlin-3 activated p53 in all the ALL cell lines; however, induction of apoptosis was dependent on PTEN status.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Imidazoles / pharmacology. Leukemia, Lymphoid / drug therapy. Leukemia, Lymphoid / metabolism. Microtubule-Associated Proteins / antagonists & inhibitors. Neoplasm Proteins / antagonists & inhibitors. Piperazines / pharmacology. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. Signal Transduction / drug effects
  • [MeSH-minor] Acute Disease. Apoptosis. Cell Death. Chromones / pharmacology. Drug Synergism. Humans. Inhibitor of Apoptosis Proteins. Morpholines / pharmacology. PTEN Phosphohydrolase / metabolism. RNA, Small Interfering. Transfection. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483299.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA123490
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Chromones; 0 / Imidazoles; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Morpholines; 0 / Neoplasm Proteins; 0 / Piperazines; 0 / RNA, Small Interfering; 0 / nutlin 3; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


28. Small TN, Young JW, Castro-Malaspina H, Prockop S, Wilton A, Heller G, Boulad F, Chiu M, Hsu K, Jakubowski A, Kernan NA, Perales MA, O'Reilly RJ, Papadopoulos EB: Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant; 2007 Feb;13(2):235-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
  • Results of allogeneic hematopoietic stem cell transplantation (HCT) to treat advanced leukemia or myelodysplastic syndrome (MDS) remain poor due to excessive relapse and transplant-related mortality.
  • To improve transplant outcome in this patient population, 43 patients (median age, 46.1 years) with high-risk or advanced lymphoid (n = 5) or myeloid malignancy (n = 38) were prospectively enrolled on a pilot trial of cytoreduction with intravenous busulfan and melphalan followed by an unmodified HLA-A, -B, and -DRbeta1-matched related (n = 18) or unrelated (n = 25) HCT.
  • Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and methotrexate.
  • Seventeen patients had unfavorable cytogenetics, 8 patients underwent transplantation for secondary MDS or acute myelogenous leukemia, and 4 patients had relapsed after a previous allogeneic transplantation.
  • The cumulative incidence of grade II-IV acute GVHD was 24%, and that of extensive chronic GVHD was 7%.
  • With a minimum follow-up of 18 months, the estimated 3-year overall survival is 37% and the estimated disease-free survival (DFS) is 33%.
  • For 18 patients with MDS (< or = RAEB-2) or high-risk myeloproliferative disorder, the estimated 3 year DFS is 61%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods


29. Shih LY, Liang DC, Fu JF, Wu JH, Wang PN, Lin TL, Dunn P, Kuo MC, Tang TC, Lin TH, Lai CL: Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement. Leukemia; 2006 Feb;20(2):218-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement.
  • The fusion transcripts of MLL rearrangement [MLL(+)] in acute myeloid leukemia (AML) and their clinicohematologic correlation have not be well characterized in the previous studies.
  • We used Southern blot analysis to screen MLL(+) in de novo AML.
  • [MeSH-major] Leukemia, Myeloid / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Child, Preschool. Female. Gene Duplication. Histone-Lysine N-Methyltransferase. Humans. Infant. Infant, Newborn. Male. Middle Aged. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16341046.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


30. Claus JA, Brady MT, Lee J, Donohue KA, Sait SN, Ferrone S, Wetzler M: T-Cell activation by t(9;22) acute lymphoblastic leukemia-derived dendritic-like cells is associated with increased tapasin expression. Cancer Immunol Immunother; 2006 Feb;55(2):160-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-Cell activation by t(9;22) acute lymphoblastic leukemia-derived dendritic-like cells is associated with increased tapasin expression.
  • Dendritic-like cells from t(9;22) acute lymphoblastic leukemia (ALL) blasts can activate T cells, while the original unmodified leukemic blasts cannot.
  • Seven t(9;22) ALL patient samples and one cell line were studied for APM component expression utilizing a unique panel of recently developed monoclonal antibodies and a recently developed intracellular staining technique.
  • In addition, the HLA class I antigen cell surface expression was measured.
  • These results provide a potential mechanism for the ability of t(9;22) ALL-derived dendritic-like cells to induce T-cell activation and, suggest that tapasin upregulation may serve as a marker to standardize and monitor the quality of the dendritic-like cells used in immunotherapy.
  • [MeSH-major] Antiporters / biosynthesis. Dendritic Cells / immunology. Immunoglobulins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Antigen Presentation / immunology. Antigens, CD / biosynthesis. Antigens, CD / immunology. Cell Line, Tumor. Histocompatibility Antigens Class I / biosynthesis. Histocompatibility Antigens Class I / immunology. Humans. In Situ Hybridization, Fluorescence / methods. Membrane Transport Proteins. Translocation, Genetic / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16010586.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16056; United States / NCI NIH HHS / CA / CA 67108
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antiporters; 0 / Histocompatibility Antigens Class I; 0 / Immunoglobulins; 0 / Membrane Transport Proteins; 0 / tapasin
  •  go-up   go-down


31. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, Fenk R, Hinke A, Haas R, Kobbe G: Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant; 2005 Jun;35(11):1089-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
  • The combination of Cyclosporin A (CSA) and Methotrexate (MTX) is considered to be the standard regimen for the prevention of graft-versus-host disease (GVHD) after stem cell transplantation (SCT) from HLA-identical siblings.
  • We retrospectively compared CSA/MTX and CSA/MMF in 93 patients (median age 35 years, range 17-59 years, male subjects 48, female subjects 45) with acute myeloid leukemia (n=33), myelodysplastic syndrome (MDS) (n=3), acute lymphoblastic leukemia (ALL) (n=20) or chronic myeloid leukemia (n=37) who received CSA/MMF (n=26) or CSA/MTX (n=67) as GVHD prophylaxis following high-dose therapy and allogeneic SCT from HLA-identical siblings.
  • No statistically significant differences were found in overall survival, relapse rate, treatment-related mortality and acute or chronic GVHD.
  • [MeSH-major] Cyclosporine / administration & dosage. Graft vs Host Disease / prevention & control. Immunosuppressive Agents / administration & dosage. Methotrexate / administration & dosage. Mycophenolic Acid / administration & dosage. Mycophenolic Acid / analogs & derivatives. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Female. HLA Antigens. Histocompatibility. Histocompatibility Testing. Humans. Leukemia / mortality. Leukemia / therapy. Living Donors. Male. Middle Aged. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Recurrence. Retrospective Studies. Siblings. Time Factors. Transplantation Conditioning. Transplantation, Homologous / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Bone Marrow Transplant. 2006 Jan;37(2):235-6; author reply 236-7 [16284607.001]
  • (PMID = 15821769.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


32. Klobusicka M, Kusenda J, Babusikova O: Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis. Neoplasma; 2005;52(3):211-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
  • The purpose of this study was to assess the possible relationship between the cytochemical enzyme profile and immunophenotypic characteristics of distinct acute myeloid leukemia (AML) subtypes in discrete stages of leukemic cells maturation.
  • The immunophenotype was examined for the maturation dependent myeloid antigens CD13, CD33, CD11b, CD14, CD15, CD65, CD36, cytoplasmic MPO, non-lineage associated CD34 and HLA-DR antigens, lymphoid- associated antigens CD7, CD4, CD38 as well as natural killer cell associated marker CD56.
  • Flow cytometry by double marker staining and visualization of pathologic cells in dot plots reflected immunophenotypic aberrancy and degree of cell maturation.
  • Notwithstanding that the cytochemical analysis of AML subtypes not sufficiently identifies the distinct aberrancies in heterogeneous leukemic blast cell populations, evaluation of the cytochemical profile in connection with immunophenotyping may help to classify the AML patients to relevant subtypes with more accuracy.
  • [MeSH-major] Granulocyte Precursor Cells / enzymology. Immunophenotyping. Leukemia, Myeloid / classification. Leukemia, Myeloid / enzymology
  • [MeSH-minor] Acute Disease. Adult. Antigens, CD / analysis. Azo Compounds. Carboxylic Ester Hydrolases / analysis. Child. Female. HLA-DR Antigens / analysis. Humans. Male. Naphthalenes. Peroxidase / analysis

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875082.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Azo Compounds; 0 / HLA-DR Antigens; 0 / Naphthalenes; 9YDL1Q990E / Sudan Black B; EC 1.11.1.7 / Peroxidase; EC 3.1.1.- / Carboxylic Ester Hydrolases; EC 3.1.1.- / naphthylbutyrate esterase
  •  go-up   go-down


33. Linabery AM, Jurek AM, Duval S, Ross JA: The association between atopy and childhood/adolescent leukemia: a meta-analysis. Am J Epidemiol; 2010 Apr 1;171(7):749-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between atopy and childhood/adolescent leukemia: a meta-analysis.
  • Atopic disease is hypothesized to be protective against several malignancies, including childhood/adolescent leukemia.
  • To summarize the available epidemiologic evidence, the authors performed a meta-analysis of associations between atopy/allergies, asthma, eczema, hay fever, and hives and childhood/adolescent leukemia, acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML).
  • Odds ratios for atopy/allergies were 1.42 (95% confidence interval (CI): 0.60, 3.35) for 3 studies of leukemia overall, 0.69 (95% CI: 0.54, 0.89) for 6 studies of ALL, and 0.87 (95% CI: 0.62, 1.22) for 2 studies of AML, with high levels of heterogeneity detected for leukemia overall and ALL.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Obstet Gynaecol. 1987 Aug;94(8):721-3 [3311129.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2658-70 [19173295.001]
  • [Cites] Pediatr Infect Dis J. 1988 May;7(5 Suppl):S10-2 [2840629.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]
  • [Cites] BMJ. 1989 Nov 18;299(6710):1259-60 [2513902.001]
  • [Cites] J Epidemiol Community Health. 1989 Dec;43(4):352-5 [2614325.001]
  • [Cites] Tumori. 1990 Oct 31;76(5):413-9 [2256184.001]
  • [Cites] J Autoimmun. 1992 Apr;5 Suppl A:363-71 [1503633.001]
  • [Cites] Cancer Causes Control. 1993 Jul;4(4):361-8 [8347786.001]
  • [Cites] Leukemia. 1994 May;8(5):856-64 [8182942.001]
  • [Cites] Cancer Detect Prev. 1994;18(4):241-52 [7982234.001]
  • [Cites] Arch Pediatr Adolesc Med. 1995 May;149(5):553-8 [7735412.001]
  • [Cites] BMJ. 1997 Sep 13;315(7109):629-34 [9310563.001]
  • [Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]
  • [Cites] Cancer Causes Control. 1998 May;9(3):285-98 [9684709.001]
  • [Cites] Klin Padiatr. 1998 Jul-Aug;210(4):185-91 [9743951.001]
  • [Cites] BMJ. 1998 Dec 5;317(7172):1562-3 [9836655.001]
  • [Cites] Clin Exp Allergy. 1998 Nov;28 Suppl 5:39-44; discussion 50-1 [9988446.001]
  • [Cites] Curr Probl Dermatol. 1999;28:1-8 [10374044.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):585-90 [10408870.001]
  • [Cites] Crit Rev Oncog. 1999;10(3):247-60 [10468184.001]
  • [Cites] J Natl Cancer Inst. 1957 Dec;19(6):1087-94 [13502763.001]
  • [Cites] Cancer Causes Control. 2000 Apr;11(4):303-7 [10843442.001]
  • [Cites] Am J Epidemiol. 2000 Sep 1;152(5):480-6 [10981463.001]
  • [Cites] J Paediatr Child Health. 2001 Aug;37(4):397-9 [11532063.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):350-5 [11875698.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):69-75 [11905816.001]
  • [Cites] Stat Med. 2002 Jun 15;21(11):1539-58 [12111919.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):255-60 [12673688.001]
  • [Cites] Chem Immunol. 2000;78:50-61 [12847718.001]
  • [Cites] J Allergy Clin Immunol. 2003 Aug;112(2):252-62 [12897728.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):139-45 [14710221.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):579-84 [14962726.001]
  • [Cites] N Engl J Med. 1972 Jul 20;287(3):107-10 [5032269.001]
  • [Cites] Br Med J. 1973 May 26;2(5864):482-3 [4736507.001]
  • [Cites] J Med. 1973;4(5):276-81 [4520972.001]
  • [Cites] Prev Med. 1974 Mar;3(1):165-70 [4815275.001]
  • [Cites] Prev Med. 1974 Sep;3(3):361-9 [4415641.001]
  • [Cites] J Natl Cancer Inst. 1976 May;56(5):891-8 [994201.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Br Med J. 1958 Jun 28;1(5086):1495-508 [13546604.001]
  • [Cites] J Chronic Dis. 1965 Feb;18:113-32 [14258467.001]
  • [Cites] JAMA. 1964 May 4;188:459 [14125221.001]
  • [Cites] J Am Acad Dermatol. 2004 Nov;51(5 Suppl):S151-5 [15577757.001]
  • [Cites] Paediatr Perinat Epidemiol. 2005 Mar;19(2):152-64 [15787890.001]
  • [Cites] Immunol Allergy Clin North Am. 2005 Nov;25(4):621-39 [16257629.001]
  • [Cites] J Investig Allergol Clin Immunol. 2005;15(3):161-6 [16261950.001]
  • [Cites] Haematologica. 2006 Feb;91(2):240-3 [16461310.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3124-32 [16395696.001]
  • [Cites] Lancet. 2006 Aug 26;368(9537):733-43 [16935684.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(17):3028-33 [16945522.001]
  • [Cites] Int J Cancer. 2007 Aug 15;121(4):819-24 [17390373.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):416-32 [18074355.001]
  • [Cites] Eur J Pediatr. 2008 Jun;167(6):697-8 [17619899.001]
  • [Cites] Br J Cancer. 2008 Nov 18;99(10):1668-72 [19002185.001]
  • [Cites] Blood Cells Mol Dis. 2009 Mar-Apr;42(2):99-104 [19049852.001]
  • [Cites] Vital Health Stat 10. 2009 Jan;(239):1-80 [19326838.001]
  • [Cites] Leukemia. 1988 Feb;2(2):120-5 [3278171.001]
  • (PMID = 20228139.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA099936; United States / NCI NIH HHS / CA / T32CA099936
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  • [Other-IDs] NLM/ PMC2877483
  •  go-up   go-down


34. Abdullah S, Diezi M, Sung L, Dupuis LL, Geary D, Abla O: Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children. Pediatr Blood Cancer; 2008 Jul;51(1):59-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROCEDURE: A retrospective chart review of all children with leukemia/lymphoma diagnosed between November 2002 and April 2004 who received sevelamer during their initial admission was conducted.
  • Nine children had acute lymphoblastic leukemia, one had acute myeloid leukemia and 3 had non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18240167.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Phosphates; 0 / Chelating Agents; 0 / Phosphates; 0 / Polyamines; 97Z1WI3NDX / calcium phosphate; 9YCX42I8IU / Sevelamer
  •  go-up   go-down


35. Taub JW, Ge Y: Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer; 2005 Jan;44(1):33-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been recognized that chromosomal abnormalities in childhood leukemia, are linked to both leukemogenesis and segregate patients into prognostic treatment groups.
  • This is best exemplified in cases of children with Down syndrome (DS), who have significantly higher risks of developing leukemia compared to non-DS children and distinctive treatment outcomes, particularly in cases of acute myeloid leukemia (AML).
  • The high event-free survival (EFS) rates of DS AML patients and in particular, patients with megakaryocytic leukemia (AMkL), at least in part reflects an increased sensitivity to cytosine arabinoside (ara-C) secondary to increased expression of the chromosome 21-localized gene, cystathionine-beta-synthase, and potentially global mechanisms which increase the susceptibility of cells to undergo apoptosis.
  • Hyperdiploid acute lymphoblastic leukemia (ALL) cells with extra copies of chromosome 21, generate higher levels of the active methotrexate (MTX) metabolite, MTX polyglutamates.
  • Microarray technology should lead to the identification of additional gene targets linked to the treatment response of specific cytogenetic leukemia subgroups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosomes, Human, Pair 21. Down Syndrome / complications. Leukemia, Megakaryoblastic, Acute / drug therapy. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / metabolism. Antineoplastic Agents, Alkylating / therapeutic use. Child. Disease-Free Survival. Humans. Methotrexate / adverse effects. Methotrexate / metabolism. Methotrexate / therapeutic use. Prognosis

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15390307.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA92308
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 45
  •  go-up   go-down


36. Timuragaoglu A, Dizlek S, Uysalgil N, Tosun O, Yamac K: Methylenetetrahydrofolate reductase C677T polymorphism in adult patients with lymphoproliferative disorders and its effect on chemotherapy. Ann Hematol; 2006 Dec;85(12):863-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because folate is the cornerstone in DNA synthesis, we analysed herein if the polymorphisms in MTHFR gene can alter the susceptibility of lymphoproliferative disease risk and if it has an effect on chemotherapy response.
  • One hundred fifty-six patients with lymphoid malignancies and 82 healthy controls were included into the study.
  • Neither gene frequencies nor allel frequencies were found to increase lymphoproliferative disease risk significantly in both overall group and subgroups.
  • Although it was not statistically significant, we found a 2.7-fold increased risk in acute lymphocytic leukaemia (ALL)/Burkitt lymphoma patients with TT genotype [odds ratio (OR), 2.7; 95% confidence interval (CI), 0.88-8.2] than CC genotype but a 1.7-fold decreased risk with TT genotype in diffuse large B-cell lymphoma (DLBCL; OR, 0.58; 95% CI, 0.17-1.88) and a 1.8-fold decreased risk in Hodgkin's lymphoma with TT genotype (OR, 0.55; 95% CI, 0.10-2.87) than CC genotype.
  • The chemotherapy response was analysed in DLBCL, Hodgkin's lymphoma and ALL/Burkitt's lymphoma because these patients received standard chemotherapy protocols.
  • As a conclusion, MTHFR C677T polymorphism does not increase the risk of lymphoproliferative disease, and it does not have an effect on chemotherapy response significantly; however, the patients with TT genotype have a slightly increased risk for ALL, and they also respond worse than CC genotype.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / genetics. Female. Genetic Predisposition to Disease. Genotype. Hodgkin Disease / drug therapy. Hodgkin Disease / genetics. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / genetics. Male. Middle Aged. Risk. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Hematol. 2007 May;86(5):389 [17211521.001]
  • (PMID = 16944145.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


37. Hafiz MG, Mannan MA: Nutritional status at initial presentation in childhood acute lymphoblastic leukemia and its effect on induction of remission. Mymensingh Med J; 2008 Jul;17(2 Suppl):S46-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutritional status at initial presentation in childhood acute lymphoblastic leukemia and its effect on induction of remission.
  • This prospective study was aimed to evaluate the nutritional status at initial presentation in childhood acute lymphoblastic leukemia (ALL) and to ascertain the effects of nutrition on induction of remission.


38. Gustafsson B, Bogdanovic G: Specific viruses were not detected in Guthrie cards from children who later developed leukemia. Pediatr Hematol Oncol; 2007 Dec;24(8):607-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific viruses were not detected in Guthrie cards from children who later developed leukemia.
  • There are hypotheses concerning infectious mechanism in the development of acute lymphoblastic leukemia (ALL).
  • [MeSH-major] DNA Tumor Viruses. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology. Tumor Virus Infections / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18092251.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Rozanov S, Keren O, Karni A: The specificity of memory for a highly trained finger movement sequence: Change the ending, change all. Brain Res; 2010 May 17;1331:80-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The specificity of memory for a highly trained finger movement sequence: Change the ending, change all.
  • How are highly trained movement sequences represented in long-term memory?
  • Here we show that the gains attained in the performance of a well-trained sequence of finger movements can be expressed only when the order of the movements is exactly as practiced.
  • Ten young adults were trained to perform a given 5-element sequence of finger-to-thumb opposition movements with their left hand.
  • Movements were analyzed using video based tracking.
  • Three weeks of training resulted, along with improved accuracy, in robustly shortened movement times as well as shorter finger-to-thumb touch times.
  • However, there was little transfer of these gains in speed to the execution of the same component movements arranged in a new order.
  • Moreover, even when the only change was the omission of the one before final movement of the trained sequence (Omit sequence), the initial movements of the sequence were significantly slowed down, although these movements were identical to the initial movements of the trained sequence.
  • Our results support the notion that a well-trained sequence of finger movements can be represented, in the adult motor system, as a singular, co-articulated, unit of movement, in which even the initial component movements are contingent on the subsequent, anticipated, ones.
  • Because of co-articulation related anticipatory effects, gains in fluency and accuracy acquired in training on a specific movement sequence cannot be expressed in full in the execution of the trained component movements or of a full segment of the trained sequence, if followed by a different ending segment.
  • [MeSH-major] Memory / physiology. Motor Skills / physiology
  • [MeSH-minor] Adult. Female. Fingers / innervation. Fingers / physiology. Humans. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Memory.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier B.V.
  • (PMID = 20298683.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


40. Visser O, van Wijnen JH, van Leeuwen FE: Incidence of cancer in the area around Amsterdam Airport Schiphol in 1988-2003: a population-based ecological study. BMC Public Health; 2005;5:127
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found a statistically significantly increased incidence of hematological malignancies (SIR 1.12, 95% confidence interval [CI]: 1.05, 1.19), mainly due to high rates for non-Hodgkin lymphoma (SIR 1.22, 95% CI: 1.12, 1.33) and acute lymphoblastic leukemia (SIR 1.34, 95% CI: 0.95, 1.83).

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ind Med. 1990;18(3):303-5 [2220835.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):647-52 [15252832.001]
  • [Cites] Anticancer Res. 1993 Mar-Apr;13(2):411-7 [8517656.001]
  • [Cites] Soc Sci Med. 1993 Sep;37(6):771-7 [8211293.001]
  • [Cites] Eur J Cancer. 1994;30A(4):469-73 [8018404.001]
  • [Cites] Occup Environ Med. 1995 Jun;52(6):374-9 [7627313.001]
  • [Cites] Eur J Cancer. 1995 Oct;31A(11):1822-9 [8541107.001]
  • [Cites] Environ Health Perspect. 1995 Nov;103 Suppl 8:219-24 [8741787.001]
  • [Cites] Int J Epidemiol. 1996 Aug;25(4):729-36 [8921449.001]
  • [Cites] Ned Tijdschr Geneeskd. 1997 Mar 8;141(10):468-73 [9173287.001]
  • [Cites] Scand J Work Environ Health. 1998 Aug;24(4):255-61 [9754856.001]
  • [Cites] Ned Tijdschr Geneeskd. 1983 Aug 20;127(34):1516-25 [6633686.001]
  • [Cites] Br Med J. 1976 Dec 25;2(6051):1525-36 [1009386.001]
  • [Cites] Environ Health Perspect. 1978 Feb;22:23-31 [648488.001]
  • [Cites] Scand J Work Environ Health. 1999 Oct;25(5):436-41 [10569464.001]
  • [Cites] Rev Environ Health. 2000 Jan-Jun;15(1-2):83-96 [10939086.001]
  • [Cites] Stat Med. 2000 Sep 15-30;19(17-18):2569-78 [10960872.001]
  • [Cites] Int J Epidemiol. 2001 Aug;30(4):839-45 [11511614.001]
  • [Cites] Occup Environ Med. 2001 Dec;58(12):769-73 [11706142.001]
  • [Cites] Environ Res. 2002 Mar;88(3):182-7 [12051796.001]
  • [Cites] Cancer Causes Control. 2002 Aug;13(6):563-71 [12195646.001]
  • [Cites] Toxicol Lett. 2004 Apr 1;149(1-3):295-300 [15093276.001]
  • [Cites] Int J Cancer. 1991 Apr 1;47(6):803-10 [2010224.001]
  • (PMID = 16332253.001).
  • [ISSN] 1471-2458
  • [Journal-full-title] BMC public health
  • [ISO-abbreviation] BMC Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Vehicle Emissions
  • [Other-IDs] NLM/ PMC1325225
  •  go-up   go-down


41. Heng JL, Chen YC, Quah TC, Liu TC, Yeoh AE: Dedicated cytogenetics factor is critical for improving karyotyping results for childhood leukaemias - experience in the National University Hospital, Singapore 1989-2006. Ann Acad Med Singapore; 2010 Feb;39(2):102-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedicated cytogenetics factor is critical for improving karyotyping results for childhood leukaemias - experience in the National University Hospital, Singapore 1989-2006.
  • INTRODUCTION: Childhood leukaemia accounts for more than 40% of new childhood cancer cases.
  • Unfortunately, karyotyping of childhood leukaemia is difficult, laborious and often unsuccessful.
  • Among them, 369 newly diagnosed and relapsed childhood acute leukaemia cases [281 acute lymphoblastic leukaemia (ALL) and 88 acute myeloid leukaemia (AML)] have been diagnosed at NUH.
  • [MeSH-major] Cytogenetic Analysis / methods. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20237730.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


42. Bender A: How similar are those molecules after all? Use two descriptors and you will have three different answers. Expert Opin Drug Discov; 2010 Dec;5(12):1141-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How similar are those molecules after all? Use two descriptors and you will have three different answers.
  • IMPORTANCE OF THE FIELD: Molecular similarity searching (ligand-based virtual screening) is one of the routine computational techniques used in drug discovery and pharmacological research.
  • However, while a large number of descriptors exist, there are no general guidelines whatsoever which descriptors work better and which descriptors should be used in the different cases.
  • AREAS COVERED IN THIS REVIEW: This review provides a brief overview of current molecular descriptors and databases used for their evaluation, followed by a critical discussion of their differences.
  • WHAT THE READER WILL GAIN: After reading this review, the reader will be aware of how very differently molecular descriptors assess similarities of molecules, and the performance that can be realistically expected from them.
  • TAKE HOME MESSAGE: Molecular descriptors come in a variety of forms, and they show vast differences in assessing the similarity between molecules.
  • Virtual screening performance of many descriptors is often lower than expected, compared to 'dumb' descriptors while some simple methods such as circular fingerprints offer surprisingly good performance in many cases.
  • The choice of the right benchmark library is crucial, many of which are summarized in this review.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22822717.001).
  • [ISSN] 1746-045X
  • [Journal-full-title] Expert opinion on drug discovery
  • [ISO-abbreviation] Expert Opin Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Grieco A, Miele L, Pompili M, Biolato M, Vecchio FM, Grattagliano I, Gasbarrini G: Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all. J Hepatol; 2009 Jun;50(6):1273-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all.
  • The episode was regarded as an adverse drug reaction after exclusion of other possible causes of acute liver disease and the prompt normalization of liver function tests after Equisterol had been discontinued.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Complementary and Integrative Medicine.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. LOVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Hepatol. 2010 Mar;52(3):466
  • (PMID = 19398239.001).
  • [ISSN] 1600-0641
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Biological Products; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Hypolipidemic Agents; 0 / Plant Extracts; 0 / Plant Gums; 0 / guggulu extract; 0 / red yeast rice; 9LHU78OQFD / Lovastatin; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


44. Deremer DL, Ustun C, Natarajan K: Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther; 2008 Nov;30(11):1956-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
  • BACKGROUND: Nilotinib, a second-generation tyrosine kinase inhibitor (TKI) formerly known as AMN107, was approved by the US Food and Drug Administration (FDA) on October 29, 2007, for the treatment of adult patients with chronic-phase (CP) and accelerated-phase (AP) Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) resistant to or intolerant of prior treatment that included imatinib.
  • OBJECTIVE: The purpose of this review was to evaluate the pharmacology, pharmacokinetic properties, and pharmacodynamic properties of nilotinib; results of clinical trials in patients with CML, Ph+ acute lymphoblastic leukemia (ALL), and gastrointestinal stromal tumors (GISTs); and potential drug interactions.
  • Search terms included, but were not limited to, nilotinib, AMN107, chronic myelogenous leukemia, acute lymphoblastic leukemia, bcr-abl, imatinib resistance, adverse events, pharmacology, and clinical trials.
  • RESULTS: Nilotinib is an orally bioavailable derivative of imatinib with improved specificity toward the breakpoint cluster region-Abelson murine leukemia (bcr-abl) viral protooncogene.
  • Of patients whose disease had progressed to AP, nilotinib was associated with major cytogenetic response in 32%; complete cytogenetic response in 19%; and CHR in 30%.
  • At 12 months, an estimated 56% of patients lacked progression of disease, and the estimated overall survival rate was 82%.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use
  • [MeSH-minor] Animals. Clinical Trials as Topic. Fusion Proteins, bcr-abl. Gastrointestinal Stromal Tumors / drug therapy. Humans. Models, Biological. Molecular Structure. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


45. Shalapour S, Eckert C, Seeger K, Pfau M, Prada J, Henze G, Blankenstein T, Kammertoens T: Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia. J Mol Med (Berl); 2010 Mar;88(3):249-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia.
  • Childhood acute lymphoblastic leukemia (ALL) is caused by malignant immature lymphocytes.
  • Given the high plasticity of cells, we searched for leukemia-associated genetic aberrations and immunoglobulin (IG) gene rearrangements in mesenchymal stem cells (MSC) from childhood B-cell precursor ALL patients.
  • MSC from all ten ALL patients analyzed presented the chromosomal translocations that had been detected in leukemia cells (TEL-AML1, E2A-PBX1, or MLL rearrangement).
  • Leukemia-specific IG gene rearrangements were detected in the MSC from three ALL patients.
  • The detection of leukemia-associated genetic aberrations in MSC indicates a clonal relationship between MSC and leukemia cells and suggests their involvement in the pathogenesis and/or pathophysiology of childhood ALL.
  • [MeSH-major] Mesenchymal Stromal Cells / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Mol Med (Berl). 2010 Mar;88(3):219-22 [20135087.001]
  • [Cites] Leukemia. 1999 Dec;13(12):1901-28 [10602411.001]
  • [Cites] Cell Death Differ. 2009 May;16(5):749-57 [19219067.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Nature. 2007 Sep 27;449(7161):473-7 [17851532.001]
  • [Cites] Bone. 1996 Nov;19(5):421-8 [8922639.001]
  • [Cites] Science. 2008 Jan 18;319(5861):336-9 [18202291.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):338-41 [15549096.001]
  • [Cites] Genes Dev. 1991 Mar;5(3):358-68 [1672117.001]
  • [Cites] Nat Rev Immunol. 2006 Feb;6(2):107-16 [16491135.001]
  • [Cites] Blood Rev. 2001 Mar;15(1):49-59 [11333138.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):449-54 [15626757.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(2):257-68 [17981026.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9142-9 [17909019.001]
  • [Cites] Exp Hematol. 1996 Jan;24(1):1-10 [8536785.001]
  • [Cites] Hum Gene Ther. 1997 Sep 20;8(14 ):1695-700 [9322872.001]
  • [Cites] J Cell Physiol. 1996 Mar;166(3):618-30 [8600166.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1442-9 [15735032.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6838-49 [17934490.001]
  • [Cites] Science. 1997 Apr 4;276(5309):71-4 [9082988.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Nature. 2002 Jul 4;418(6893):41-9 [12077603.001]
  • [Cites] Leuk Res. 2006 Aug;30(8):993-1003 [16448696.001]
  • [Cites] PLoS Biol. 2007 Mar;5(3):e43 [17298184.001]
  • [Cites] Stem Cells Dev. 2009 Apr;18(3):497-510 [18598159.001]
  • [Cites] Nat Med. 2005 Jun;11(6):630-7 [15908956.001]
  • [Cites] Cancer Genet Cytogenet. 2003 May;143(1):89-91 [12742162.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):483-95 [18538732.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3956-63 [10339505.001]
  • [Cites] Blood. 1994 Jun 1;83(11):3271-8 [8193362.001]
  • [Cites] Cell. 2008 Apr 18;133(2):250-64 [18423197.001]
  • [Cites] Blood. 2009 Apr 2;113(14 ):3287-96 [19147788.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1515-27 [19357701.001]
  • [Cites] Science. 2008 Nov 28;322(5906):1377-80 [19039135.001]
  • [Cites] J Cell Sci. 2006 Apr 15;119(Pt 8):1477-82 [16551697.001]
  • [Cites] Leukemia. 2009 Apr;23(4):664-72 [19151777.001]
  • [Cites] Blood. 1994 Apr 15;83(8):2238-47 [8161789.001]
  • [Cites] EMBO J. 1997 Jun 16;16(12):3644-54 [9218805.001]
  • [Cites] Blood. 2004 May 15;103(10):3798-804 [14656882.001]
  • [Cites] Stem Cells. 2006 Dec;24(12):2753-65 [16931776.001]
  • [Cites] Cell. 2007 Jul 13;130(1):63-75 [17599403.001]
  • [Cites] Bone Marrow Transplant. 2003 Mar;31(5):339-45 [12634724.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1377-88 [17604725.001]
  • [Cites] Methods Mol Med. 2004;91:175-82 [14573937.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] N Engl J Med. 2004 Jul 15;351(3):250-9 [15254283.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] Lancet. 2000 May 13;355(9216):1688-91 [10905245.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Science. 1999 Apr 2;284(5411):143-7 [10102814.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] Hematol Oncol. 2006 Mar;24(1):3-6 [16270377.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):542-5 [11932747.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):413-20 [12163366.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):639-49 [12951583.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1978-82 [9369435.001]
  • [Cites] Blood. 1971 Jul;38(1):81-6 [5283675.001]
  • [Cites] Cell. 2004 Mar 5;116(5):639-48 [15006347.001]
  • [Cites] Leukemia. 2006 May;20(5):777-84 [16511515.001]
  • [Cites] Blood. 1978 Jun;51(6):1039-44 [274158.001]
  • (PMID = 20155409.001).
  • [ISSN] 1432-1440
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


46. Rajić V, Aplenc R, Debeljak M, Prestor VV, Karas-Kuzelicki N, Mlinaric-Rascan I, Jazbec J: Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma; 2009 Oct;50(10):1693-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood.
  • The hypothesis was tested in a cohort of 76 long-term survivals of acute lymphoblastic leukemia in childhood.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cardiomyopathies / genetics. Genetic Association Studies. Heart / drug effects. Myocardium / pathology. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Survivors


47. Gümüş H, Per H, Kumandaş S, Yikilmaz A: Reversible posterior leukoencephalopathy syndrome in childhood: report of nine cases and review of the literature. Neurol Sci; 2010 Apr;31(2):125-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reversible posterior leukoencephalopathy syndrome (RPLS) is recently described disorder with typical radiological findings in the posterior regions of the cerebral hemisphere and cerebellum.
  • We presented nine patients with RPLS who had primary diagnoses such as acute post-streptococcal glomerulonephritis, idiopathic hypertension, the performing of intravenous immunoglobulin for infection with crescentic glomerulonephritis, erythrocyte transfusion for severe iron deficiency, L: -asparaginase treatment for acute lymphoblastic leukemia and performing of granulocyte-colony stimulating factor for ulcerative colitis due to neutropenia.
  • Early recognition of RPLS as complication during different diseases and therapy in childhood may facilitate precise diagnosis and appropriate treatment.
  • [MeSH-major] Posterior Leukoencephalopathy Syndrome / diagnosis
  • [MeSH-minor] Adolescent. Brain / pathology. Child. Diagnosis, Differential. Early Diagnosis. Female. Humans. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 Aug;21(7):1199-206 [10954269.001]
  • [Cites] J Neurol. 2002 Jun;249(6):780-1 [12173578.001]
  • [Cites] Neurology. 1999 Apr 12;52(6):1285-8 [10214762.001]
  • [Cites] Epilepsia. 1998 Mar;39(3):295-9 [9578048.001]
  • [Cites] Stroke. 1997 May;28(5):1082-5 [9158653.001]
  • [Cites] Pediatr Radiol. 2005 Jul;35(7):722-7 [15756541.001]
  • [Cites] Pediatr Nephrol. 2001 Jul;16(7):601-3 [11465812.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Mar;19(3):591 [9541327.001]
  • [Cites] Radiology. 2001 Jun;219(3):756-65 [11376265.001]
  • [Cites] Arch Gynecol Obstet. 2005 Jan;271(1):79-85 [15480723.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Jun-Jul;23(6):1038-48 [12063238.001]
  • [Cites] Pediatr Neurol. 1999 Mar;20(3):241-3 [10207937.001]
  • [Cites] Pediatr Neurol. 2006 Mar;34(3):245-7 [16504799.001]
  • [Cites] Eur J Neurol. 2006 Mar;13(3):309-10 [16618354.001]
  • [Cites] Ann Intern Med. 1995 Oct 15;123(8):598-600 [7677301.001]
  • [Cites] Intern Med J. 2005 Feb;35(2):83-90 [15705136.001]
  • [Cites] Nephrol Dial Transplant. 1989;4(12):1065-9 [2517327.001]
  • [Cites] AJR Am J Roentgenol. 1992 Aug;159(2):379-83 [1632361.001]
  • [Cites] Pediatr Infect Dis J. 2006 Jan;25(1):85-7 [16395114.001]
  • [Cites] Curr Opin Pediatr. 1999 Dec;11(6):512-8 [10590909.001]
  • [Cites] Radiology. 1991 Aug;180(2):475-8 [2068315.001]
  • [Cites] Eur J Pediatr. 2004 Dec;163(12):728-30 [15322868.001]
  • [Cites] Pediatr Neurol. 2001 May;24(5):361-4 [11516610.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):198-203 [16123992.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Jun-Jul;16(6):1344-6 [7677037.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):447-55 [18079186.001]
  • [Cites] Radiology. 2000 Nov;217(2):371-6 [11058630.001]
  • [Cites] Pediatr Nephrol. 2003 Nov;18(11):1161-6 [14505162.001]
  • [Cites] Pediatr Nephrol. 1993 Apr;7(2):194-5 [8476718.001]
  • [Cites] Neurology. 2001 Feb 13;56(3):388-91 [11171907.001]
  • [Cites] Neurology. 1998 Nov;51(5):1369-76 [9818862.001]
  • [Cites] J Comput Assist Tomogr. 2007 Jan-Feb;31(1):148-56 [17259848.001]
  • [Cites] N Engl J Med. 1996 Feb 22;334(8):494-500 [8559202.001]
  • [Cites] Clin Neurol Neurosurg. 1997 Aug;99(3):222-6 [9350407.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Jan;18(1):101-6 [9010526.001]
  • [Cites] Postgrad Med J. 2001 Jan;77(903):24-8 [11123390.001]
  • [Cites] Blood. 2003 Jan 15;101(2):415-9 [12393443.001]
  • [Cites] Neurology. 1997 Oct;49(4):1174-5 [9339716.001]
  • [Cites] BMJ. 1989 Nov 18;299(6710):1258-9 [2513901.001]
  • (PMID = 19809787.001).
  • [ISSN] 1590-3478
  • [Journal-full-title] Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • [ISO-abbreviation] Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 42
  •  go-up   go-down


48. Nahar R, Müschen M: Pre-B cell receptor signaling in acute lymphoblastic leukemia. Cell Cycle; 2009 Dec;8(23):3874-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-B cell receptor signaling in acute lymphoblastic leukemia.
  • B cell lineage ALL represents by far the most frequent malignancy in children and is also common in adults.
  • In a recent study on 111 cases of pre-B cell-derived human ALL, we found that ALL cells carrying a BCR-ABL1-gene rearrangement lack expression of a functional pre-B cell receptor in virtually all cases.
  • In a proof-of-principle experiment, we studied pre-B cell receptor function during progressive leukemic transformation of pre-B cells in BCR-ABL1-transgenic mice: Interestingly, signaling from the pre-B cell receptor and the oncogenic BCR-ABL1 kinase are mutually exclusive and only "crippled" pre-B cells that fail to express a functional pre-B cell receptor are permissive to transformation by BCR-ABL1.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11464-9 [10500199.001]
  • [Cites] Immunity. 1999 Jan;10(1):117-25 [10023776.001]
  • [Cites] J Immunol. 2005 Jan 1;174(1):367-75 [15611260.001]
  • [Cites] Blood. 2005 May 1;105(9):3434-41 [15650057.001]
  • [Cites] J Exp Med. 2005 Jun 6;201(11):1837-52 [15939795.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13266-71 [16141323.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3559-66 [16046533.001]
  • [Cites] Oncogene. 2006 Feb 16;25(7):1118-24 [16205638.001]
  • [Cites] Oncogene. 2006 Aug 24;25(37):5180-6 [16636677.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2703-11 [16794253.001]
  • [Cites] J Exp Med. 2006 Dec 25;203(13):2829-40 [17130299.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Immunity. 2007 Mar;26(3):335-44 [17363301.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] J Exp Med. 2007 May 14;204(5):1157-66 [17485517.001]
  • [Cites] J Immunol. 2007 Aug 15;179(4):2055-9 [17675462.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Nat Immunol. 2008 Jun;9(6):623-31 [18488031.001]
  • [Cites] Blood. 2009 Feb 12;113(7):1483-92 [19047679.001]
  • [Cites] J Exp Med. 2009 Aug 3;206(8):1739-53 [19620627.001]
  • [Cites] Nature. 1973 Jun 1;243(5405):290-3 [4126434.001]
  • [Cites] Science. 1999 Dec 3;286(5446):1954-7 [10583958.001]
  • [Cites] Immunity. 1999 Nov;11(5):547-54 [10591180.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):57-60 [10615128.001]
  • [Cites] J Exp Med. 2000 Jan 3;191(1):23-32 [10620602.001]
  • [Cites] Blood. 2000 Jul 1;96(1):9-23 [10891425.001]
  • [Cites] Immunol Rev. 2000 Jun;175:104-11 [10933595.001]
  • [Cites] Immunity. 2000 Aug;13(2):243-53 [10981967.001]
  • [Cites] Immunol Rev. 2000 Dec;178:75-90 [11213809.001]
  • [Cites] Annu Rev Immunol. 2001;19:595-621 [11244048.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] J Immunol. 2002 Jun 15;168(12):6286-93 [12055243.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):1029-35 [12370281.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1057-69 [12453414.001]
  • [Cites] Nat Immunol. 2003 Jan;4(1):38-43 [12436112.001]
  • [Cites] Nature. 2003 May 22;423(6938):452-6 [12761551.001]
  • [Cites] J Exp Med. 2004 Mar 1;199(5):673-85 [14993251.001]
  • [Cites] Nature. 1985 Jun 27-Jul 3;315(6022):758-61 [2989703.001]
  • [Cites] Cell. 1993 Sep 10;74(5):833-43 [8104101.001]
  • [Cites] Cell. 1994 Apr 8;77(1):133-43 [8156589.001]
  • [Cites] Immunity. 1996 Dec;5(6):537-49 [8986714.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] J Exp Med. 1998 Jan 5;187(1):71-7 [9419212.001]
  • [Cites] Immunity. 1998 Jul;9(1):93-103 [9697839.001]
  • [Cites] Immunity. 1998 Oct;9(4):543-53 [9806640.001]
  • [Cites] J Clin Invest. 1999 Oct;104(8):1115-21 [10525050.001]
  • (PMID = 19901533.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA137606; None / None / / R01 CA137060-01A1; United States / NCI NIH HHS / CA / R21 CA152497; None / None / / R01 CA139032-01; United States / NCI NIH HHS / CA / R01 CA139032-01; United States / NCI NIH HHS / CA / R01 CA137060-01A1; United States / NCI NIH HHS / CA / R01 CA139032; United States / NCI NIH HHS / CA / R01CA139032; United States / NCI NIH HHS / CA / R01 CA137060
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABI1 protein, human; 0 / Abi1 protein, mouse; 0 / Adaptor Proteins, Signal Transducing; 0 / B cell linker protein; 0 / Cytoskeletal Proteins; 0 / Pre-B Cell Receptors; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  • [Other-IDs] NLM/ NIHMS230959; NLM/ PMC4047560
  •  go-up   go-down


49. Uyttebroeck A, Suciu S, Laureys G, Robert A, Pacquement H, Ferster A, Marguerite G, Mazingue F, Renard M, Lutz P, Rialland X, Mechinaud F, Cavé H, Baila L, Bertrand Y, Children's Leukaemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC): Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer; 2008 Apr;44(6):840-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial.
  • From June 1989 through to November 1998, 121 children with newly diagnosed T-cell lymphoblastic lymphoma (T-LBL) were included in the EORTC 58881 trial conducted by the Children's Leukaemia Group.
  • Cranial irradiation, prophylactic cranial and local, was omitted, even for patients with central nervous involvement at diagnosis.
  • An intensive acute lymphoblastic leukaemia type chemotherapy regimen without irradiation leads to a high cure and survival rate in childhood T-LBL without an increased CNS recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342502.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10-CA11488-18; United States / NCI NIH HHS / CA / 5U10-CA11488-19; United States / NCI NIH HHS / CA / 5U10-CA11488-20; United States / NCI NIH HHS / CA / 5U10-CA11488-21; United States / NCI NIH HHS / CA / 5U10-CA11488-22; United States / NCI NIH HHS / CA / 5U10-CA11488-23; United States / NCI NIH HHS / CA / 5U10-CA11488-24; United States / NCI NIH HHS / CA / 5U10-CA11488-25; United States / NCI NIH HHS / CA / 5U10-CA11488-26; United States / NCI NIH HHS / CA / 5U10-CA11488-27; United States / NCI NIH HHS / CA / 5U10-CA11488-28; United States / NCI NIH HHS / CA / 5U10-CA11488-29; United States / NCI NIH HHS / CA / 5U10-CA11488-30; United States / NCI NIH HHS / CA / 5U10-CA11488-31; United States / NCI NIH HHS / CA / 5U10-CA11488-32; United States / NCI NIH HHS / CA / 5U10-CA11488-33; United States / NCI NIH HHS / CA / 5U10-CA11488-34; United States / NCI NIH HHS / CA / 5U10-CA11488-35; United States / NCI NIH HHS / CA / 5U10-CA11488-36
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Philippet P; Otten J; Plouvier E; Béhar C; Boutard P; Millot F; Waterkeyn C; Velde IV; Solbu G
  •  go-up   go-down


50. Schindler JW, Van Buren D, Foudi A, Krejci O, Qin J, Orkin SH, Hock H: TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Cell Stem Cell; 2009 Jul 2;5(1):43-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia.
  • The initial steps in the pathogenesis of acute leukemia remain incompletely understood.
  • The TEL-AML1 gene fusion, the hallmark translocation in Childhood Acute Lymphoblastic Leukemia and the first hit, occurs years before the clinical disease, most often in utero.
  • TEL-AML1 renders mice prone to malignancy after chemical mutagenesis when expressed in hematopoietic stem cells (HSCs), but not in early lymphoid progenitors.
  • We reveal that TEL-AML1 markedly increases the number of HSCs and predominantly maintains them in the quiescent (G(0)) stage of the cell cycle.
  • [MeSH-major] Bone Marrow Cells / metabolism. Core Binding Factor Alpha 2 Subunit / genetics. Hematopoietic Stem Cells / metabolism. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. Oncogenes


51. Jegalian AG, Facchetti F, Jaffe ES: Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol; 2009 Nov;16(6):392-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Normally found in small quantities in primary and secondary lymphoid organs, PDCs accumulate in a variety of inflammatory conditions, including Kikuchi-Fujimoto lymphadenopathy, hyaline-vascular Castleman disease, and autoimmune diseases, and in certain malignancies such as classical Hodgkin lymphoma and carcinomas.
  • Demonstrating potential for neoplastic transformation reflective of varying stages of maturation, clonal proliferations range from PDC nodules most commonly associated with chronic myelomonocytic leukemia to the rare but highly aggressive malignancy now known as blastic plasmacytoid dendritic cell neoplasm (BPDCN).
  • Formerly called blastic natural killer cell lymphoma or CD4/CD56 hematodermic neoplasm, BPDCN, unlike natural killer cell lymphomas, is not associated with Epstein-Barr virus infection and is generally not curable with treatment regimens for non-Hodgkin lymphomas.
  • In fact, this entity is no longer considered to be a lymphoma and instead represents a unique precursor hematopoietic neoplasm.
  • Acute leukemia therapy regimens may lead to sustained clinical remission of BPDCN, with bone marrow transplantation in first complete remission potentially curative in adult patients.
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Lineage. Child. Child, Preschool. Female. Humans. Leukemia, Myeloid / pathology. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / pathology. Male. Toll-Like Receptors / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851130.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Toll-Like Receptors
  • [Number-of-references] 151
  •  go-up   go-down


52. Chow EJ, Simmons JH, Roth CL, Baker KS, Hoffmeister PA, Sanders JE, Friedman DL: Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation. Biol Blood Marrow Transplant; 2010 Dec;16(12):1674-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation.
  • Survivors of childhood acute lymphoblastic leukemia (ALL) may face an increased risk of metabolic and cardiovascular late effects.
  • To determine the prevalence of and risk factors for adverse cardiometabolic traits in a contemporary cohort of pediatric ALL survivors, we recruited 48 off-therapy patients in remission treated with conventional chemotherapy and 26 treated with total body irradiation (TBI)-based hematopoietic cell transplantation (HCT) in this cross-sectional pilot study.
  • Other risk factors included any cranial radiation exposure and family history of cardiometabolic disease.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6):1521-5 [15585763.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):81-9 [15994749.001]
  • [Cites] Circulation. 2006 Apr 18;113(15):1888-904 [16618833.001]
  • [Cites] Diabet Med. 2006 May;23(5):469-80 [16681555.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(12):1109-17 [16699534.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4401-7 [16954158.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1765-72 [17047152.001]
  • [Cites] Cardiovasc Res. 2007 Apr 1;74(1):11-8 [17140553.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Aug;29(8):529-34 [17762493.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3816-21 [17652222.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3463-71 [17664354.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2313-20 [17896787.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):160-4 [18206681.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):177-84 [18206686.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):185-90 [18206687.001]
  • [Cites] Diabetes Metab. 2008 Feb;34(1):2-11 [18093861.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Apr;22(2):319-42, viii [18395153.001]
  • [Cites] Bone Marrow Transplant. 2008 May;41(9):797-804 [18195686.001]
  • [Cites] Best Pract Res Clin Haematol. 2008 Jun;21(2):129-38 [18503981.001]
  • [Cites] Br J Haematol. 2008 Jul;142(1):11-26 [18430191.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Nov;69(5):819-27 [18429947.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Nov;30(11):815-22 [18989158.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5537-43 [18809605.001]
  • [Cites] Bone Marrow Transplant. 2009 Jan;43(1):49-54 [18724397.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3698-704 [19564534.001]
  • [Cites] PLoS Genet. 2009 Dec;5(12):e1000768 [20011104.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):170-81 [20056636.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Apr;16(4):515-24 [19961945.001]
  • [Cites] Lancet. 2000 Sep 16;356(9234):993-7 [11041401.001]
  • [Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]
  • [Cites] J Nutr. 2001 Aug;131(8):2184-91 [11481415.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):427-36 [12588201.001]
  • [Cites] Arch Pediatr Adolesc Med. 2003 Aug;157(8):821-7 [12912790.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Feb;26(2):81-90 [14767193.001]
  • [Cites] Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76 [15286277.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3558-62 [15337805.001]
  • [Cites] J Pediatr. 2004 Oct;145(4):439-44 [15480363.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Can J Public Health. 1986 Sep-Oct;77(5):359-62 [3791117.001]
  • [Cites] Am J Epidemiol. 1996 Jun 15;143(12):1219-28 [8651220.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5 [8768873.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1650-6 [9614255.001]
  • [Cites] Transplantation. 2004 Nov 15;78(9):1376-83 [15548978.001]
  • (PMID = 20685399.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024975-01; United States / NCRR NIH HHS / RR / UL1 RR025014-01; United States / NCRR NIH HHS / RR / TL1 RR024978; United States / NCRR NIH HHS / RR / KL2 RR024977; None / None / / UL1 RR025014-01; United States / NCRR NIH HHS / RR / UL1RR025014; United States / NCRR NIH HHS / RR / UL1RR024975; United States / NCRR NIH HHS / RR / UL1 RR025014; United States / NCRR NIH HHS / RR / UL1 RR024975
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ NIHMS211258; NLM/ PMC2975816
  •  go-up   go-down


53. Leal-Ugarte E, Gutiérrez-Angulo M, Macías-Gómez NM, Peralta-Leal V, Durán-González J, De La Luz Ayala-Madrigal M, Partida-Pérez M, Barros-Núñez P, Ruiz-Díaz D, Moreno-Ortiz JM, Peregrina-Sandoval J, Meza-Espinoza JP: MDR1 C3435T polymorphism in Mexican children with acute lymphoblastic leukemia and in healthy individuals. Hum Biol; 2008 Aug;80(4):449-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDR1 C3435T polymorphism in Mexican children with acute lymphoblastic leukemia and in healthy individuals.
  • To determine the influence of the MDR1 C3435T polymorphism on the development of childhood acute lymphoblastic leukemia (ALL), we studied 107 children with ALL and 111 healthy subjects.
  • [MeSH-major] P-Glycoprotein / genetics. Polymorphism, Genetic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317599.001).
  • [ISSN] 0018-7143
  • [Journal-full-title] Human biology
  • [ISO-abbreviation] Hum. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / P-Glycoprotein; 0 / P-Glycoproteins
  •  go-up   go-down


54. Koufopantelis P, Georgakakou S, Kazanis M, Giaginis C, Margeli A, Papargiri S, Panderi I: Direct injection liquid chromatography/positive ion electrospray ionization mass spectrometric quantification of methotrexate, folinic acid, folic acid and ondansetron in human serum. J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov 15;877(30):3850-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A rapid liquid chromatography/positive ion electrospray mass spectrometric assay (LC/ESI-MS) was developed for the quantitation of methotrexate, folinic acid, folic acid and ondansetron in human serum.
  • The assay was based on 100microL serum samples, following acetonitrile precipitation of proteins and filtration that enabled direct injection into the LC/MS system.
  • The assay was found to be linear in the concentration range of 0.01-25.00microgmL(-1) for methotrexate and 0.01-5.00microgmL(-1) for folic acid, folinic acid and ondansetron.
  • The method can be used to quantify methotrexate, folinic acid, folic acid and ondansetron in human serum covering a variety of clinical studies and it was applied to the analysis of human serum samples obtained from children with acute lymphoblastic leukemia.

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19828383.001).
  • [ISSN] 1873-376X
  • [Journal-full-title] Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
  • [ISO-abbreviation] J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 4AF302ESOS / Ondansetron; 935E97BOY8 / Folic Acid; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


55. Yanada M, Kiyoi H, Murata M, Suzuki M, Iwai M, Yokozawa T, Baba H, Emi N, Naoe T: Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med; 2006;45(5):259-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia.
  • RESULTS: A total of 31 patients with acute leukemia who developed febrile neutropenia were enrolled in the study.
  • Underlying diseases consisted of acute myeloid leukemia (n=15) and acute lymphoblastic leukemia (n=3).
  • [MeSH-minor] Adolescent. Adult. Algorithms. Echinocandins. Female. Fever / etiology. Humans. Leukemia, Myeloid / complications. Lipopeptides. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Prospective Studies

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595990.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Lipopeptides; 0 / Lipoproteins; 0 / Peptides, Cyclic; R10H71BSWG / micafungin
  •  go-up   go-down


56. Pichiorri F, Trapasso F, Palumbo T, Aqeilan RI, Drusco A, Blaser BW, Iliopoulos D, Caligiuri MA, Huebner K, Croce CM: Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35. Clin Cancer Res; 2006 Jun 01;12(11 Pt 1):3494-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35.
  • Adenovirus 5 (Ad5) virus or adeno-associated viral vectors have been used to study the tumor suppressor function of FHIT in solid tumors, but these tools have not been effective in leukemias.
  • EXPERIMENTAL DESIGN: Infection efficiency of Ad5/F35-FHIT and Ad5/F35-GFP viruses was tested in leukemia cell lines that lacked FHIT expression, and biological effects of successful infection were assessed.
  • An acute myelogenous leukemia, a chronic myelogenous leukemia, and four acute lymphoblastic leukemia human cell lines were examined as well as two EBV-transformed B lymphoblastoid cell lines that expressed endogenous FHIT.
  • RESULTS: Two of four acute lymphoblastic leukemia cell lines, Jurkat and MV4;11, which were efficiently infected with Ad5/F35-FHIT, underwent growth suppression and massive induction of apoptosis without apparent activation of caspase-8 or caspase-2 and late activation of caspase-3.
  • The two remaining infected acute lymphoblastic leukemia cell lines, Molt-3 and RS4;11, were apparently unaffected.
  • Restoration of FHIT expression in the chronic myelogenous leukemia K562 cell line and the acute myelogenous leukemia KG1a cell line also induced apoptosis but at later time points than seen in the acute lymphoblastic leukemia Jurkat and MV4;11 cell lines. I.v. injection of Ad5/F35-FHIT-infected Jurkat cells resulted in abrogation of tumorigenicity in the NOD/SCID xenogeneic engraftment model.
  • CONCLUSION: FHIT restoration in some FHIT-deficient leukemia cells induces both antiproliferative and proapoptotic effects involving the intrinsic caspase apoptotic pathway.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Adenoviruses, Human / genetics. Gene Expression Regulation, Neoplastic / genetics. Genetic Therapy / methods. Leukemia / genetics. Neoplasm Proteins / genetics
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / genetics. Cell Cycle. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Models, Animal. Drug Screening Assays, Antitumor. Enzyme Inhibitors / pharmacology. Gene Transfer Techniques. Genetic Vectors / genetics. Green Fluorescent Proteins / genetics. Humans. Kinetics. Mice. Mice, Inbred NOD. Mice, SCID. Structure-Activity Relationship. Transplantation, Heterologous. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res. 2016 Dec 15;22(24):6304 [27856602.001]
  • (PMID = 16740775.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA56036; United States / NCI NIH HHS / CA / CA77738; United States / NCI NIH HHS / CA / CA78890; United States / NCI NIH HHS / CA / CA89341
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; 147336-22-9 / Green Fluorescent Proteins; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


57. Claviez A, Eckert C, Seeger K, Schrauder A, Schrappe M, Henze G, von Stackelberg A: Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia. Haematologica; 2006 Feb;91(2):272-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia.
  • We treated three children with relapsed or refractory CD20 positive B-cell precursor acute lymphoblastic leukemia with rituximab in combination with chemotherapy, which produced a decreasing or persistent low positive minimal residual disease load.
  • Two children subsequently underwent allogeneic stem cell transplantation and remain in complete remission at days +399 and +332.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antigens, CD20. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16461321.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


58. Schmitz NM, Hirt A, Aebi M, Leibundgut K: Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia. Am J Pathol; 2006 Sep;169(3):1074-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia.
  • In Nalm-6 acute lymphoblastic leukemia extracts, serine 608 is phosphorylated by CDK4/6 complexes but not by CDK2.
  • Serine 612 phosphorylation by CDK4 also occurred in extracts of childhood acute lymphoblastic leukemia cells but not in extracts of mobilized CD34+ hemopoietic progenitor cells.
  • This phenomenon could contribute to the commitment of childhood acute lymphocytic leukemia cells to proliferate and explain their refractoriness to differentiation-inducing agents.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Cyclin-Dependent Kinase 2 / metabolism. Cyclin-Dependent Kinase 4 / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Protein Processing, Post-Translational. Retinoblastoma-Like Protein p107 / metabolism
  • [MeSH-minor] Antigens, CD34. Cell Differentiation / drug effects. Cell Line, Tumor. Cell-Free System / metabolism. Drug Resistance, Neoplasm / drug effects. G1 Phase / drug effects. Hematopoietic Stem Cells / metabolism. Humans. Indoles / pharmacology. Multiprotein Complexes / metabolism. Phosphorylation / drug effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Retinoblastoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Jan 27;19(4):562-70 [10698526.001]
  • [Cites] Cell. 2000 Mar 31;101(1):79-89 [10778858.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4320-3 [10969768.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 7;275(3):877-84 [10973815.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19358-66 [12646568.001]
  • [Cites] Cell. 2003 Aug 22;114(4):431-43 [12941272.001]
  • [Cites] Nat Genet. 2003 Sep;35(1):25-31 [12923533.001]
  • [Cites] EMBO J. 2003 Sep 15;22(18):4794-803 [12970191.001]
  • [Cites] Curr Biol. 2003 Oct 14;13(20):1775-85 [14561402.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):27-36 [14700606.001]
  • [Cites] Biochem Biophys Res Commun. 2004 May 7;317(3):779-86 [15081408.001]
  • [Cites] Cell. 2004 Apr 16;117(2):239-51 [15084261.001]
  • [Cites] Cell. 2004 Aug 20;118(4):477-91 [15315760.001]
  • [Cites] Cell. 2004 Aug 20;118(4):493-504 [15315761.001]
  • [Cites] Science. 1989 Nov 3;246(4930):603-8 [2683075.001]
  • [Cites] Cell. 1991 May 3;65(3):381-93 [2018973.001]
  • [Cites] Cell. 1991 Oct 18;67(2):293-302 [1655277.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):6914-8 [8346196.001]
  • [Cites] Mol Cell Biol. 1993 Oct;13(10):6501-8 [8413249.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):2066-76 [8114738.001]
  • [Cites] Leukemia. 1994 Jun;8(6):940-5 [8207988.001]
  • [Cites] Cell. 1994 Jul 15;78(1):161-72 [8033208.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3215-20 [8622916.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1093-106 [16360038.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14317-22 [11114185.001]
  • [Cites] Leukemia. 2001 Jan;15(1):1-9 [11243375.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14):4773-84 [11416152.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):83-6 [11544530.001]
  • [Cites] EMBO Rep. 2001 Sep;2(9):794-9 [11520855.001]
  • [Cites] J Biochem Mol Biol. 2003 Jan 31;36(1):60-5 [12542976.001]
  • [Cites] J Biol Chem. 1996 Apr 5;271(14):8313-20 [8626527.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):7173-81 [8943373.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):7060-9 [9003781.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):249-54 [9010227.001]
  • [Cites] Br J Haematol. 1997 Feb;96(2):366-8 [9029026.001]
  • [Cites] Mol Biol Cell. 1997 Feb;8(2):287-301 [9190208.001]
  • [Cites] J Biol Chem. 1997 May 9;272(19):12738-46 [9139732.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Mol Cell Biol. 1997 Oct;17(10):5771-83 [9315635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10699-704 [9380698.001]
  • [Cites] Oncogene. 1997 Dec 4;15(23):2855-66 [9419977.001]
  • [Cites] Mol Cell Biol. 1998 Feb;18(2):753-61 [9447971.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):765-9 [9635861.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10493-8 [9724731.001]
  • [Cites] J Biol Chem. 1999 Apr 2;274(14):9463-71 [10092628.001]
  • [Cites] Pediatr Res. 1999 May;45(5 Pt 1):692-6 [10231867.001]
  • [Cites] Cell. 1999 Sep 17;98(6):859-69 [10499802.001]
  • [Cites] Mol Cell. 2004 Dec 3;16(5):831-7 [15574337.001]
  • [Cites] J Biochem. 2005 Mar;137(3):381-6 [15809340.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):591-8 [15950907.001]
  • [Cites] Stem Cells. 2005 Aug;23(7):1002-11 [15941859.001]
  • [Cites] Nat Cell Biol. 2005 Aug;7(8):831-6 [16007079.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1400-6 [15878982.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1783-7 [16107892.001]
  • (PMID = 16936279.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Indoles; 0 / Multiprotein Complexes; 0 / Retinoblastoma-Like Protein p107; 114719-57-2 / fascaplysine; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  • [Other-IDs] NLM/ PMC1698824
  •  go-up   go-down


59. Asfour IA, Fayek MH, El-Kourashy SA, Youssef SR, El-Gohary GM, Mohamed OF: Correlation of telomerase activity to apoptosis and survival in adult acute lymphoblastic leukemia: an Egyptian single-center study. Ann Hematol; 2008 Mar;87(3):213-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of telomerase activity to apoptosis and survival in adult acute lymphoblastic leukemia: an Egyptian single-center study.
  • The goal of this study was to investigate the levels and relationship of telomerase activity to apoptosis and its impact on the survival of Egyptian adult acute lymphoblastic leukemia patients.
  • Telomerase activity was quantified by polymerase chain reaction (PCR) and detected by enzyme-linked immunosorbent assay (ELISA), while apoptosis was measured at the single-cell level by fluorescence in situ detection using flow cytometry in 15 control subjects and 40 acute lymphoblastic leukemia (ALL) patients at presentation.
  • This makes the measurement of telomerase activity in ALL patients a potential tool to predict disease with unfavorable outcome and a candidate tumor marker.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / metabolism. Neoplasm Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Telomerase / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Disease-Free Survival. Egypt. Enzyme Activation / genetics. Female. Follow-Up Studies. Humans. Male. Middle Aged. Polymerase Chain Reaction. Predictive Value of Tests. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18175116.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


60. Kapoor S, Marwaha R, Majumdar S, Ghosh S: Apoptosis induction by Maackia amurensis agglutinin in childhood acute lymphoblastic leukemic cells. Leuk Res; 2008 Apr;32(4):559-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis induction by Maackia amurensis agglutinin in childhood acute lymphoblastic leukemic cells.
  • Malignant transformation is known to be associated with changes in cell surface carbohydrate-architecture, which can be detected by lectins.
  • In the present study, Maackia amurensis agglutinin (MAA), specific for NeuNAcalpha(2-->3)Gal/GalNAc showed strong binding with lymphoblasts of children having acute lymphoblastic leukemia (ALL) as compared to cells from children with non-hematological disorders ("Controls").
  • [MeSH-major] Apoptosis / drug effects. Phytohemagglutinins / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Blotting, Western. Cell Line. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Glycoproteins / metabolism. Humans. Lymphocytes / metabolism. Male. Neuraminidase / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889364.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Phytohemagglutinins; 0 / leukoagglutinins, plants; EC 3.2.1.- / sialidase L; EC 3.2.1.18 / Neuraminidase
  •  go-up   go-down


61. Gandemer V, Auclerc MF, Perel Y, Vannier JP, Le Gall E, Demeocq F, Schmitt C, Piguet C, Stephan JL, Lejars O, Debre M, Jonveaux P, Cayuela JM, Chevret S, Leverger G, Baruchel A, FRALLE group: Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study. BMC Cancer; 2009;9:14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study.
  • BACKGROUND: We explored the heterogeneity of philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL) in a study of the effect of early features on prognosis in children.
  • Overall five-year disease-free survival (DFS) was 42 +/- 9.7%.
  • The combination of available tools such as minimal residual disease assessment with determination of these simple factors could be useful for refining indications for BMT in the current era of tyrosine-kinase inhibitor-based therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Bone Marrow / drug effects. Leukocyte Count. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage
  • [MeSH-minor] Acute Disease. Adolescent. Age Factors. Anthracyclines. Asparaginase. Benzamides. Bone Marrow Transplantation. Child. Child, Preschool. Cortisone. Female. Humans. Imatinib Mesylate. Infant. Male. Prednisone / administration & dosage. Recurrence. Treatment Outcome. Vincristine. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Apr;19(4):628-35 [15744351.001]
  • [Cites] Br J Haematol. 2005 Apr;129(1):35-44 [15801953.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1341-9 [17312329.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2791-3 [17119111.001]
  • [Cites] Haematologica. 2007 Dec;92(12):1723-4 [18056006.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):447-53 [17968326.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1496-503 [18349402.001]
  • [Cites] Blood. 2002 Jul 1;100(1):43-7 [12070006.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1700-6 [12970767.001]
  • [Cites] Bone Marrow Transplant. 2004 Jan;33(1):39-45 [14566329.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1043-9 [14525776.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1292-5 [7632935.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1493-6 [9305603.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7209-19 [16243790.001]
  • (PMID = 19144139.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 5J49Q6B70F / Vincristine; 8A1O1M485B / Imatinib Mesylate; EC 3.5.1.1 / Asparaginase; V27W9254FZ / Cortisone; VB0R961HZT / Prednisone; FRALLE 93 protocol
  • [Other-IDs] NLM/ PMC2629767
  • [Investigator] Pautard B; Bauduer JF; Abgrall JF; Berthou C; Paillard C; Kanold J; Couillault G; Damay M; de Lumley L; Michel G; Thuret I; Chambost H; Bordigoni P; Sommel D; Leblanc T; Schaison G; Tabone MD; Donadieu J; Landman-Parker J; Auvrignon A; Thomas C; Fisher A; Dommergues JP; Bader-Meunier B; Bernaudin F; Lemerle S; Choulot J; Doireau V; Edan C; Bergeron C; Schneider P; Lamagnere JP; Berger C; Cornu G; Vermylen C
  •  go-up   go-down


62. Pombo-de-Oliveira MS, Koifman S, Brazilian Collaborative Study Group of Infant Acute Leukemia: Infant acute leukemia and maternal exposures during pregnancy. Cancer Epidemiol Biomarkers Prev; 2006 Dec;15(12):2336-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infant acute leukemia and maternal exposures during pregnancy.
  • Infant acute leukemia (IAL) has a unique profile characterized by the high incidence of translocations involving the MLL gene located at the 11q23 region.
  • [MeSH-major] Leukemia, Myeloid / etiology. Maternal Exposure. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Prenatal Exposure Delayed Effects
  • [MeSH-minor] Acute Disease. Brazil / epidemiology. Case-Control Studies. Female. Histone-Lysine N-Methyltransferase. Hospitals. Humans. Infant. Infant, Newborn. Male. Maternal-Fetal Exchange. Myeloid-Lymphoid Leukemia Protein / genetics. Pregnancy. Translocation, Genetic

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2331 [17164352.001]
  • (PMID = 17164354.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


63. Rivera GK, Zhou Y, Hancock ML, Gajjar A, Rubnitz J, Ribeiro RC, Sandlund JT, Hudson M, Relling M, Evans WE, Pui CH: Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer; 2005 Jan 15;103(2):368-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
  • BACKGROUND: The authors studied the clinical outcome of 106 children with acute lymphoblastic leukemia (ALL) who developed a bone marrow recurrence as the first adverse event after contemporary intensified therapy.
  • On multivariate analysis, time to first disease recurrence and blast cell lineage were found to be independent predictors of a second EFS (P = 0.008 and P = 0.028, respectively).
  • The 5-year EFS estimate in patients with an initial disease remission of >/= 36 months was 42.6% +/- 7.8% but was only 12.5% +/- 3.9% among children with a short duration of disease remission (< 36 months).
  • These estimates were 28.7% +/- 4.9% and 5.0% +/- 3.4%, respectively, for B blast and T blast cell lineages.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / epidemiology. Bone Marrow / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Age Distribution. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Incidence. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Probability. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Risk Assessment. Severity of Illness Index. Sex Distribution. Survival Rate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • (PMID = 15599932.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


64. Fullmer A, O'Brien S, Kantarjian H, Jabbour E: Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opin Emerg Drugs; 2010 Mar;15(1):1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging therapy for the treatment of acute lymphoblastic leukemia.
  • IMPORTANCE OF THE FIELD: Over the last few decades, advances in acute lymphoblastic leukemia (ALL) therapy have led to long-term survival rates of > 80% in children; however, comparable rates have yet to be achieved in adults, and a large majority of patients relapse from their disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drugs, Investigational / therapeutic use. Neoplasm, Residual / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Child. Disease-Free Survival. Humans. Salvage Therapy / methods. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055690.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Investigational
  • [Number-of-references] 68
  •  go-up   go-down


65. Möricke A, Zimmermann M, Reiter A, Gadner H, Odenwald E, Harbott J, Ludwig WD, Riehm H, Schrappe M: Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr; 2005 Nov-Dec;217(6):310-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
  • Large progress has been made in the treatment of acute lymphoblastic leukemia (ALL) of childhood and adolescence over the past 30 years.
  • The proportion of T-ALL as compared to precursor B-cell ALL (pB-ALL) was lower in younger children, due to an incidence peak of pB-ALL in toddlers and at pre-school age compared to a constant incidence of T-ALL.
  • Within the T-ALL group, no correlation of age with sex, initial white blood cell count, CNS disease, or early treatment response was found.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] 6-Mercaptopurine / adverse effects. 6-Mercaptopurine / therapeutic use. Adolescent. Age Factors. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / adverse effects. Asparaginase / therapeutic use. Child. Child, Preschool. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Cytarabine / adverse effects. Cytarabine / therapeutic use. Daunorubicin / adverse effects. Daunorubicin / therapeutic use. Disease-Free Survival. Female. Humans. Infant. Male. Methotrexate / adverse effects. Methotrexate / therapeutic use. Multicenter Studies as Topic. Prednisolone / adverse effects. Prednisolone / therapeutic use. Prednisone / adverse effects. Prednisone / therapeutic use. Prognosis. Randomized Controlled Trials as Topic. Survival Analysis. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16307416.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol; ALL-BFM-95 protocol; BFM-86 protocol
  •  go-up   go-down


66. İrken G, Ören H, Öniz H, Çetingül N, Vergin C, Atabay B, Gülen H, Türker M, Kantar M, Yılmaz Ş: Hyperleukocytosis in childhood acute lymphoblastic leukemia: complications and treatment outcome. Turk J Haematol; 2006 Sep 5;23(3):142-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperleukocytosis in childhood acute lymphoblastic leukemia: complications and treatment outcome.
  • [Transliterated title] Çocukluk çağı akut lenfoblastik lösemisinde hiperlökositoz: komplikasyonlar, tedavi, prognoz.
  • Hyperleukocytosis, defined as a peripheral leukocyte count ≥ 100x109/L, is seen in 5-20% of newly diagnosed cases of childhood leukemia and is a poor prognostic factor.
  • In this study, we aimed to examine the presenting clinical and laboratory features, complications, and treatment outcome of 47 children with acute lymphoblastic leukemia (ALL) and hyperleukocytosis who were diagnosed and treated in four medical centers of İzmir between January 1990 and January 2001.
  • Median white blood cell count was 495x109/L (range: 107x109/L- 794x109/L).
  • Forty-two of 47 patients (90%) had hepatosplenomegaly, 5 (11%) had respiratory distress, 3 (6%) had neurologic symptoms, 3 (6%) had diffuse cervical lymphadenopathy, and 3 (6%) had acute renal failure at admission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265481.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


67. Niedzielska E, Wójcik D, Barg E, Pietras W, Sega-Pondel D, Doroszko A, Niedzielska M, Skarzyńska M, Chybicka A: [Evaluation of selected endocrine complications in patients treated with auto- and allo-haematopoietic stem cell transplantation]. Med Wieku Rozwoj; 2008 Jul-Sep;12(3):761-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of selected endocrine complications in patients treated with auto- and allo-haematopoietic stem cell transplantation].
  • AIM: The aim of this study was to evaluate the endocrine complications, in particular disorders of growth and thyroid function and glucose metabolism dysfunctions in patients treated with allo- and auto-haematopoietic stem cell transplantation (HSCT).
  • MATERIAL AND METHODS: The investigated group consisted of: I. 16 patients after auto-HSCT (6 girls, 10 boys) aged 3-20 years (average 10,8+/-) because of acute myelogenous leukaemia (n=5), non Hodgkin lymphoma (n=3), neuroblastoma (n=3), embryonal cancer (n=2), medulloblastoma (n=1), Ewing's sarcoma/PNET (n=1), hyper eosinophilic syndrome (n=1).
  • Indication for HSCT was acute lymphoblastic leukaemia (n=11), acute myelogenous leukaemia (n=5), chronic myeloid leukaemia-CML (n=6), myelodysplastic syndromes (n=2), non Hodgkin lymphoma (n=1), juvenile myelomonocytic leukemia (n=1), severe aplastic anaemia (n=1), Blackfan-Diamond anaemia (n=1), severe combined immune deficiency (n=1), rhabdomyosarcoma (n=1).
  • [MeSH-major] Endocrine System Diseases / etiology. Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia / therapy


68. Lyons R, Williams O, Morrow M, Sebire N, Hubank M, Anderson J: The RAC specific guanine nucleotide exchange factor Asef functions downstream from TEL-AML1 to promote leukaemic transformation. Leuk Res; 2010 Jan;34(1):109-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TEL-AML1 is an oncogenic fusion protein associated with childhood pre-B acute lymphoblastic leukaemia.
  • From published microarray datasets we identified the Rho Guanine Nucleotide Exchange Factor (RhoGEF) Asef to be associated with TEL-AML1 leukaemia.
  • In haemopoietic transplantation reconstitution assays Asef and TEL-AML1 together failed to induce a leukaemic phenotype.
  • [MeSH-major] Cell Transformation, Neoplastic. Core Binding Factor Alpha 2 Subunit / physiology. Guanine Nucleotide Exchange Factors / physiology. Leukemia / pathology. Oncogene Proteins, Fusion / physiology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19628279.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARHGEF4 protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Guanine Nucleotide Exchange Factors; 0 / Oncogene Proteins, Fusion; 0 / Rho Guanine Nucleotide Exchange Factors; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


69. Liu TB, Luo XF, Chen ZZ, Hu JD: [Effects of small interference RNA against c-myc on expression of c-myc and h-tert genes in acute lymphoblastic leukemia cell line Jurkat]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of small interference RNA against c-myc on expression of c-myc and h-tert genes in acute lymphoblastic leukemia cell line Jurkat].
  • This study was purposed to investigate the effect of small interfering RNA against c-myc on c-myc, h-tert gene and protein expressions in acute lymphoblastic leukemia cell line (Jurkat cells), so as to provide new methods and targets for gene therapy of leukemia.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129250.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Protein Subunits; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Small Interfering; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


70. Yadav SP, Kalra M, Anjan M, Sachdeva A: Survival outcome in childhood acute lymphoblastic leukemia in India. Pediatr Blood Cancer; 2010 Jan;54(1):178; author reply 179
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival outcome in childhood acute lymphoblastic leukemia in India.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


71. Abutalib SA, Wetzler M, Stock W: Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia. Hematol Oncol Clin North Am; 2009 Oct;23(5):1099-119, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia.
  • There has been exponential growth in our understanding of the pathobiology of acute lymphoblastic leukemia (ALL) leading to the discovery of new prognostic markers and potential new treatment strategies.
  • [MeSH-major] Pathology, Molecular / trends. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19825455.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 136
  •  go-up   go-down


72. Wilcken B: Improving child health--newborn screening for all? Ann Acad Med Singapore; 2008 Dec;37(12 Suppl):3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the last 40 years newborn screening has been an undoubted success and many thousands of children have been saved from mental retardation and other problems because of early diagnosis of their disorders.


73. Speleman F, De Preter K, Hoebeeck J, Van Roy N, Vandesompele J: [New insights into the genetic basis of neuroblastoma]. Verh K Acad Geneeskd Belg; 2007;69(4):167-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Nieuwe inzichten in de genetische basis van neuroblastoom.
  • Neuroblastoma (NB) is, next to acute lymphoblastic leukaemia, brain tumours and lymphoma the most frequent paediatric tumour (8-10%).
  • A second important part of our work focussed on the gene expression profiling of NB precursor cells.
  • Gene expression analyses of model systems developed in our lab and of a large panel of cell lines and tumours allowed us to subtract a list of candidate genes which are now under further study.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17821957.001).
  • [ISSN] 0302-6469
  • [Journal-full-title] Verhandelingen - Koninklijke Academie voor Geneeskunde van België
  • [ISO-abbreviation] Verh. K. Acad. Geneeskd. Belg.
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 49
  •  go-up   go-down


74. Bagg A: Lineage ambiguity, infidelity, and promiscuity in immunophenotypically complex acute leukemias: genetic and morphologic correlates. Am J Clin Pathol; 2007 Oct;128(4):545-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lineage ambiguity, infidelity, and promiscuity in immunophenotypically complex acute leukemias: genetic and morphologic correlates.
  • [MeSH-major] Cell Lineage / genetics. Immunophenotyping / methods. Leukemia, Lymphoid / genetics. Leukemia, Myeloid / genetics
  • [MeSH-minor] Acute Disease. Flow Cytometry. Humans. Molecular Diagnostic Techniques

  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875503.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Editorial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


75. Mittal MK: Severe hypercalcemia as a harbinger of acute lymphoblastic leukemia. Pediatr Emerg Care; 2007 Jun;23(6):397-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hypercalcemia as a harbinger of acute lymphoblastic leukemia.
  • A few days later, she developed pancytopenia when her bone marrow biopsy specimen established the diagnosis of acute lymphoblastic leukemia.
  • It can be a harbinger of acute lymphoblastic leukemia.
  • Normal complete blood cell count at presentation does not exclude the diagnosis of leukemia.
  • [MeSH-major] Hypercalcemia / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17572525.001).
  • [ISSN] 1535-1815
  • [Journal-full-title] Pediatric emergency care
  • [ISO-abbreviation] Pediatr Emerg Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Bernard N, Alberdi AJ, Tanguy ML, Brugere H, Helissey P, Hubert C, Gendrey N, Guillosson JJ, Nafziger J: Assessing the potential leukemogenic effects of 50 Hz magnetic fields and their harmonics using an animal leukemia model. J Radiat Res; 2008 Nov;49(6):565-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the potential leukemogenic effects of 50 Hz magnetic fields and their harmonics using an animal leukemia model.
  • To answer the still unresolved question of the possible leukemogenic effects of extremely low frequency magnetic fields (ELF-MFs) and of their harmonics on the incidence of B acute lymphoblastic leukemia in children, we used an animal model to explore the possible co-initiating or co-promoting effects of ELF-MFs on the development of leukemia.
  • We used a rat model in which B acute lymphoblastic leukemia is chemically induced by a nitrosurea derivative.
  • We compared body weight and survival time, percentage of bone marrow blast cells, cumulative incidence of leukemia and type of leukemia in the unexposed groups and in the groups exposed to 50 Hz MFs, with and without harmonics.
  • Significant changes in the leukemia type obtained after gamma-irradiation of the leukemia model, showed its sensitivity to a physical agent.
  • Our results do not support the hypothesis that ELF-MFs, with or without harmonics, affect the development of B acute lymphoblastic leukemia in children.
  • [MeSH-major] Leukemia, Radiation-Induced / etiology. Leukemia, Radiation-Induced / physiopathology. Risk Assessment / methods. Whole-Body Irradiation / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838845.001).
  • [ISSN] 0449-3060
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


77. Zhang Y, Hu CF, Chen J, Yan LX, Zeng YX, Shao JY: LATS2 is de-methylated and overexpressed in nasopharyngeal carcinoma and predicts poor prognosis. BMC Cancer; 2010;10:538
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LATS2 is de-methylated and overexpressed in nasopharyngeal carcinoma and predicts poor prognosis.
  • In breast cancer and acute lymphoblastic leukemia (ALL), LATS2 mRNA is downregulated and has been suggested to be a tumor suppressor.
  • In this study, we aimed to investigate the expression pattern of LATS2 and its clinicopathological involvement in nasopharyngeal carcinoma to understand its effect on cell survival.
  • METHODS: Using quantitative real time PCR and immunoblotting, the expression of LATS2 was detected in nasopharyngeal carcinoma cell lines and in the immortalized nasopharyngeal epithelial cell line NP69.
  • Functional studies showed that the suppression of LATS2 expression in nasopharyngeal carcinoma (5-8F and CNE2) cell lines by using specific small interfering (siRNA) resulted in the inhibition of growth, induction of apoptosis and S-phase cell cycle increase.
  • Overexpression of LATS2 in NP69 stimulated cell proliferation.

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Nov 15;86(10):1912-20 [10570413.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1437-42 [20080689.001]
  • [Cites] Cancer. 2000 Jul 15;89(2):242-7 [10918151.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):13-21 [12517535.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):17609-14 [12624101.001]
  • [Cites] Oncogene. 2003 Jul 10;22(28):4398-405 [12853976.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):794-9 [12874084.001]
  • [Cites] Cancer Cell. 2004 May;5(5):423-8 [15144950.001]
  • [Cites] Genes Cells. 2004 May;9(5):383-97 [15147269.001]
  • [Cites] Exp Cell Res. 2004 Aug 15;298(2):329-38 [15265683.001]
  • [Cites] EMBO J. 2004 Sep 15;23(18):3677-88 [15343267.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1037-42 [7961009.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4059-66 [15736452.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1380-5 [15746036.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2347-50 [16208412.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12405-10 [16894141.001]
  • [Cites] BMC Cancer. 2006;6:167 [16796765.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2687-700 [17015431.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765-77 [17035381.001]
  • [Cites] Neurosci Res. 2006 Dec;56(4):450-8 [17049657.001]
  • [Cites] Genes Dev. 2007 Apr 15;21(8):886-97 [17437995.001]
  • [Cites] J Biol Chem. 2007 Jun 29;282(26):19259-71 [17478426.001]
  • [Cites] J Transl Med. 2008;6:1 [18171482.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1356-64 [18472356.001]
  • [Cites] J Biol Chem. 2008 Oct 10;283(41):27534-46 [18640976.001]
  • [Cites] Circ Res. 2008 Nov 21;103(11):1309-18 [18927464.001]
  • [Cites] Curr Opin Cell Biol. 2008 Dec;20(6):638-46 [18955139.001]
  • [Cites] Blood. 2009 Feb 26;113(9):1957-66 [19005181.001]
  • [Cites] Int J Cancer. 2009 Jun 15;124(12):2942-7 [19296536.001]
  • [Cites] Radiother Oncol. 2009 Jul;92(1):105-10 [19264368.001]
  • [Cites] Int J Cancer. 2009 Oct 15;125(8):1832-41 [19582878.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]
  • (PMID = 20932276.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.7.1.11 / LATS2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2958949
  •  go-up   go-down


78. Gabriel IH, Abdalla SH, Ryley S, Bain BJ: Case 34: acute leukemia in a patient with a previous history of breast cancer. Leuk Lymphoma; 2007 Feb;48(2):403-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case 34: acute leukemia in a patient with a previous history of breast cancer.
  • A 56-year-old woman presented with acute myeloid leukemia 3 years after presenting with carcinoma of the breast.
  • Detailed investigations led to a precise diagnosis.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Leukemia, Myeloid / chemically induced
  • [MeSH-minor] Acute Disease. Cyclophosphamide / adverse effects. Doxorubicin / adverse effects. Female. Flow Cytometry. Gene Rearrangement. Histone-Lysine N-Methyltransferase. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Middle Aged. Myeloid-Lymphoid Leukemia Protein / genetics. Topoisomerase II Inhibitors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325903.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / MLL protein, human; 0 / Topoisomerase II Inhibitors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


79. Pan C, Gu LJ, Xue HL, Chen J, Dong L, Zhou M, Luo CY, Wang YP, Tang JY: [Evaluation of a modified induction chemotherapy in children with acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2007 May;45(5):324-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of a modified induction chemotherapy in children with acute lymphoblastic leukemia].
  • OBJECTIVE: To improve the treatment outcome of children with acute lymphoblastic leukemia (ALL), and to evaluate the efficacy and safety of a modified induction chemotherapy between the two protocols used to treat children with ALL in Shanghai Children's Medical Center.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphoid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Remission Induction / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697614.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis
  • [Publication-country] China
  •  go-up   go-down


80. Mejía Aranguré JM, Flores Aguilar H, Juárez Muñoz I, Vázquez Langle J, Games Eternod J, Pérez Saldívar ML, Ortega Alvarez MC, Rendón Macías ME, Gutiérrez AF: [Age of onset of different malignant tumors in childhood]. Rev Med Inst Mex Seguro Soc; 2005 Jan-Feb;43(1):25-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Age of onset of different malignant tumors in childhood].
  • [Transliterated title] Edad de aparición de los diferentes tumores malignos en la infancia.
  • OBJECTIVE: To identify the main age of onset of different malignant tumors in childhood and to describe the distribution of the different tumors in each pediatric age group.
  • RESULTS: Peak ages for hepatic, sympathetic nervous system, germ cell tumors, retinoblastoma and rhabdomyosarcoma were between 2 and 3 years of age.
  • Wilms' tumor appeared between the first and fourth years; central nervous system tumors between 4 and 5 years; acute lymphoblastic leukemia between 2 and 4 years; non-Hodgkin's lymphomas between 3 and 6 years; Hodgkin's disease between 4 and 8 years; bone tumors between 10 and 14 years.
  • In acute myeloid leukemia and carcinomas no age peak was found.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15998478.001).
  • [ISSN] 0443-5117
  • [Journal-full-title] Revista médica del Instituto Mexicano del Seguro Social
  • [ISO-abbreviation] Rev Med Inst Mex Seguro Soc
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


81. Altinkaynak S, Selimoglu MA, Turgut A, Kilicaslan B, Ertekin V: Breast-feeding duration and childhood acute leukemia and lymphomas in a sample of Turkish children. J Pediatr Gastroenterol Nutr; 2006 May;42(5):568-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast-feeding duration and childhood acute leukemia and lymphomas in a sample of Turkish children.
  • OBJECTIVES: Whether breast-feeding is associated with decreased incidence of the lymphoid malignancies in children is uncertain.
  • We evaluated childhood acute leukemia and lymphoma in relation to duration of breast-feeding.
  • METHODS: We investigated this issue in a case-control study comprising 137 patients, aged 1 to 16 years, with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin or non-Hodgkin lymphoma, in addition to 146 controls matched for age and sex.
  • Breast-feeding for a duration of 0 to 6 months, when compared with feeding of longer than 6 months, was associated with increased odds ratios (ORs) for ALL [OR = 2.44, 95% confidence interval (CI) = 1.17-5.10], AML (OR = 6.67, 95% CI = 1.32-33.69), Hodgkin lymphoma (OR = 3.33, 95% CI = 0.60-18.54), non-Hodgkin lymphoma (OR = 1.90, 95% CI = 0.68-5.34) and overall (OR = 2.54, 95% CI = 1.51-4.26).
  • CONCLUSIONS: Our findings suggest that breast-feeding of more than 6 months is protective against childhood lymphoid malignancies, especially for AML and ALL.
  • [MeSH-major] Breast Feeding. Leukemia / prevention & control. Lymphoma / prevention & control
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Female. Humans. Infant. Male. Risk Factors. Time Factors. Turkey

  • MedlinePlus Health Information. consumer health - Breastfeeding.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707982.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Silveira Vda S, Canalle R, Scrideli CA, Queiroz RG, Tone LG: Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children. Environ Mol Mutagen; 2010 Jan;51(1):48-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children.
  • Polymorphic variations of several genes associated with dietary effects and exposure to environmental carcinogens may influence susceptibility to leukemia development.
  • The objective of the present study was to evaluate the effect of the polymorphisms of debrisoquine hydroxylase (CYP2D6), epoxide hydrolase (EPHX1), myeloperoxidase (MPO), and quinone-oxoreductase (NQO1), which have been implicated in xenobiotic metabolism, on the risk of childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Cytochrome P-450 CYP2D6 / genetics. Epoxide Hydrolases / genetics. Genetic Predisposition to Disease. Granulocyte Colony-Stimulating Factor / genetics. Interleukin-3 / genetics. NAD(P)H Dehydrogenase (Quinone) / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Recombinant Fusion Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19593802.001).
  • [ISSN] 1098-2280
  • [Journal-full-title] Environmental and molecular mutagenesis
  • [ISO-abbreviation] Environ. Mol. Mutagen.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-3; 0 / Recombinant Fusion Proteins; 0 / Recombinant Proteins; 0 / myelopoietin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; EC 1.14.14.1 / Cytochrome P-450 CYP2D6; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 3.3.2.- / Epoxide Hydrolases; EC 3.3.2.9 / EPHX1 protein, human
  •  go-up   go-down


83. Craig FE, Foon KA: Flow cytometric immunophenotyping for hematologic neoplasms. Blood; 2008 Apr 15;111(8):3941-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Flow cytometric immunophenotyping remains an indispensable tool for the diagnosis, classification, staging, and monitoring of hematologic neoplasms.
  • The last 10 years have seen advances in flow cytometry instrumentation and availability of an expanded range of antibodies and fluorochromes that have improved our ability to identify different normal cell populations and recognize phenotypic aberrancies, even when present in a small proportion of the cells analyzed.
  • Phenotypically abnormal populations have been documented in many hematologic neoplasms, including lymphoma, chronic lymphoid leukemias, plasma cell neoplasms, acute leukemia, paroxysmal nocturnal hemoglobinuria, mast cell disease, myelodysplastic syndromes, and myeloproliferative disorders.
  • The past decade has also seen refinement of the criteria used to identify distinct disease entities with widespread adoption of the 2001 World Health Organization (WHO) classification.
  • This classification endorses a multiparametric approach to diagnosis and outlines the morphologic, immunophenotypic, and genotypic features characteristic of each disease entity.
  • [MeSH-major] Flow Cytometry / methods. Hematologic Neoplasms / diagnosis. Immunophenotyping / methods
  • [MeSH-minor] Hemoglobinuria, Paroxysmal / diagnosis. Humans. Plasma Cells / pathology

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18198345.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 146
  •  go-up   go-down


84. Nath CE, Dallapozza L, Eslick AE, Misra A, Carr D, Earl JW: An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia. Biomed Chromatogr; 2009 Feb;23(2):152-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
  • A novel assay for the determination of l-asparaginase activity in human plasma is described that is based on the HPLC quantitation of l-aspartic acid produced during enzyme incubation.
  • The l-asparaginase assay was linear from 0.1 to 10 U/mL activity and interday precision and accuracy were less than 13%.
  • The assay utility was established in 12 children who received E. coli l-asparaginase as treatment for acute lymphoblastic leukaemia.
  • [MeSH-major] Antineoplastic Agents / metabolism. Asparaginase / metabolism. Asparagine / metabolism. Chromatography, High Pressure Liquid / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • (PMID = 18823071.001).
  • [ISSN] 1099-0801
  • [Journal-full-title] Biomedical chromatography : BMC
  • [ISO-abbreviation] Biomed. Chromatogr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Escherichia coli Proteins; 0RH81L854J / Glutamine; 30KYC7MIAI / Aspartic Acid; 3KX376GY7L / Glutamic Acid; 6KA95X0IVO / Homoserine; 7006-34-0 / Asparagine; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


85. Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, Tjørnelund J, Dawson KM, Dupuis M, Duchosal MA: The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood; 2009 Apr 2;113(14):3276-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • APO866 inhibits nicotinamide phosphoribosyltransferase (NMPRTase), a key enzyme involved in nicotinamide adenine dinucleotide (NAD) biosynthesis from the natural precursor nicotinamide.
  • Intracellular NAD is essential for cell survival, and NAD depletion resulting from APO866 treatment elicits tumor cell death.
  • Here, we determine the in vitro and in vivo sensitivities of hematologic cancer cells to APO866 using a panel of cell lines (n = 45) and primary cells (n = 32).
  • Most cancer cells (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], mantle cell lymphoma [MCL], chronic lymphocytic leukemia [CLL], and T-cell lymphoma), but not normal hematopoietic progenitor cells, were sensitive to low concentrations of APO866 as measured in cytotoxicity and clonogenic assays.
  • The NAD depletion led to cell death.
  • At 96 hours, APO866-mediated cell death occurred in a caspase-independent mode, and was associated with mitochondrial dysfunction and autophagy.
  • Further, in vivo administration of APO866 as a single agent prevented and abrogated tumor growth in animal models of human AML, lymphoblastic lymphoma, and leukemia without significant toxicity to the animals.
  • [MeSH-minor] Animals. Cell Death / drug effects. Dose-Response Relationship, Drug. HL-60 Cells. Humans. Jurkat Cells. K562 Cells. Mice. Mice, Inbred BALB C. Mice, Nude. Tumor Cells, Cultured. U937 Cells. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2009 Jun 4;113(23):6035-7; author reply 6037-8 [19498032.001]
  • (PMID = 19196867.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylamides; 0 / Antineoplastic Agents; 0 / Cytokines; 0 / N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide; 0 / Piperidines; 0U46U6E8UK / NAD; EC 2.4.2.12 / Nicotinamide Phosphoribosyltransferase; EC 2.4.2.12 / nicotinamide phosphoribosyltransferase, human
  •  go-up   go-down


86. Wiemels JL, Zhang Y, Chang J, Zheng S, Metayer C, Zhang L, Smith MT, Ma X, Selvin S, Buffler PA, Wiencke JK: RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. Leukemia; 2005 Mar;19(3):415-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia.
  • We explored the relationship of RAS gene mutations with epidemiologic and cytogenetic factors in a case series of children with leukemia.
  • Diagnostic bone marrow samples from 191 incident leukemia cases from the Northern California Childhood Leukemia Study were typed for NRAS and KRAS codon 12 and 13 mutations.
  • Among the 142 B-cell acute lymphoblastic leukemia (ALL) cases, RAS mutations were more common among Hispanic children (P=0.11) or children born to mothers <30 years (P=0.007).
  • Those with hyperdiploidy at diagnosis (>50 chromosomes) had the highest rates of RAS mutation (P=0.02).
  • Interestingly, smoking of the father in the 3 months prior to pregnancy was reported less frequently among hyperdiploid leukemia patients than among those without hyperdiploidy (P=0.02).
  • The data suggest that RAS and high hyperdiploidy may be cooperative genetic events to produce the leukemia subtype; and furthermore, that maternal age and paternal preconception smoking or other factors associated with these parameters are critical in the etiology of subtypes of childhood leukemia.
  • [MeSH-major] Genes, ras / genetics. Mutation. Polyploidy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674422.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCHHSTP CDC HHS / PS / PS42 ES04705; United States / NCI NIH HHS / CA / R01 CA89032; United States / NIEHS NIH HHS / ES / R01 ES09137
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


87. Brouwer C, Vogels-Mentink TM, Keizer-Garritsen JJ, Trijbels FJ, Bökkerink JP, Hoogerbrugge PM, van Wering ER, Veerman AJ, De Abreu RA: Role of 5'-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment. Clin Chim Acta; 2005 Nov;361(1-2):95-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of 5'-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment.
  • At the optimal pH, assays were performed to establish Km and Vmax values.
  • [MeSH-major] 5'-Nucleotidase / metabolism. 6-Mercaptopurine / therapeutic use. Guanosine Monophosphate / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Sulfhydryl Compounds / chemistry. Thioguanine / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990089.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Sulfhydryl Compounds; 85-32-5 / Guanosine Monophosphate; E7WED276I5 / 6-Mercaptopurine; EC 3.1.3.5 / 5'-Nucleotidase; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


88. Pais A, Amare Kadam P, Raje G, Sawant M, Kabre S, Jain H, Advani S, Banavali S: Identification of various MLL gene aberrations that lead to MLL gene mutation in patients with acute lymphoblastic leukemia (ALL) and infants with acute leukemia. Leuk Res; 2005 May;29(5):517-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of various MLL gene aberrations that lead to MLL gene mutation in patients with acute lymphoblastic leukemia (ALL) and infants with acute leukemia.
  • Studies were done to investigate MLL gene aberrations using Conventional Cytogenetics, Southern blotting as well as FISH using a panel of probes on 218 cases which included 206 cases of pediatric/young adult ALL and 12 cases of infantile acute leukemias from Tata Memorial Hospital, India.
  • The incidence of MLL gene rearrangements in acute lymphoblastic leukemia (ALL) was 9.4% which included infants as well as pediatric/young adults.
  • [MeSH-major] Chromosome Aberrations. DNA-Binding Proteins / genetics. Gene Rearrangement. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. India. Infant. Karyotyping. Male. Mutation. Myeloid-Lymphoid Leukemia Protein. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755504.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


89. Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S, Savani BN, Keyvanfar K, Li Y, Kurlander R, Barrett AJ: Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood; 2009 Mar 5;113(10):2245-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.
  • Preferentially expressed antigen of melanoma (PRAME) is aberrantly expressed in hematologic malignancies and may be a useful target for immunotherapy in leukemia.
  • To determine whether PRAME is naturally immunogenic, we studied CD8(+) T-cell responses to 4 HLA-A*0201-restricted PRAME-derived epitopes (PRA100, PRA142, PRA300, PRA425) in HLA-A*0201-positive patients with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and healthy donors.
  • High PRAME expression in patient peripheral blood mononuclear cells was associated with responses to greater than or equal to 2 PRAME epitopes compared with low PRAME expression levels (4/7 vs 0/23, P = .001), suggesting a PRAME-driven T-cell response.
  • These results provide evidence for spontaneous T cell reactivity against multiple epitopes of PRAME in ALL, AML, and CML.
  • The potential for developing PRAME as a target for immunotherapy in leukemia deserves further exploration.
  • [MeSH-major] Antigens, Neoplasm / immunology. CD8-Positive T-Lymphocytes / immunology. Leukemia, Myeloid / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology


90. Im M, Lee JK, Hong YJ, Hong SI, Kang HJ, Na II, Ryoo BY, Cheon GJ, Lee HN, Chang YH: [Four cases of hematologic malignancy following radioactive iodine therapy for thyroid cancer]. Korean J Lab Med; 2008 Dec;28(6):425-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of leukemia following radioactive iodine treatment for thyroid cancer has been reported to be approximately 0.1 to 2.0% in Western countries, whereas fewer cases have been reported in Korea.
  • We hereby report four cases of secondary hematologic malignancy, who received iodine therapy for thyroid cancer after thyroidectomy: two cases of acute lymphoblastic leukemia with t(9;22)(q34;q11.2), a case of MDS with 5q deletion, and a case of MDS with normal karyotype.
  • [MeSH-major] Hematologic Neoplasms / diagnosis. Iodine Radioisotopes / adverse effects. Leukemia, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis. Thyroid Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 5. Chromosomes, Human, Pair 9. Female. Gene Deletion. Humans. Middle Aged. Myelodysplastic Syndromes / diagnosis. Myelodysplastic Syndromes / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Thyroidectomy. Translocation, Genetic

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19127106.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


91. Eguchi M, Eguchi-Ishimae M, Greaves M: Molecular pathogenesis of MLL-associated leukemias. Int J Hematol; 2005 Jul;82(1):9-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of MLL-associated leukemias.
  • Chromosome translocations disrupting the MLL gene are associated with various hematologic malignancies but are particularly common in infant and secondary therapy-related acute leukemias.
  • In leukemia, this function is subverted by breakage, recombination, and the formation of chimeric fusion with one of many alternative partners.
  • Key unresolved issues currently being addressed include the set of target genes for MLL fusions, the stem cell of origin for the leukemias, the role of additional secondary mutations, and the origins or etiology of the MLL gene fusions themselves.
  • Further elaboration of the biology of MLL gene-associated leukemia should lead to novel and specific therapeutic strategies.
  • [MeSH-major] Leukemia / genetics. Leukemia / physiopathology. Myeloid-Lymphoid Leukemia Protein / genetics. Myeloid-Lymphoid Leukemia Protein / physiology. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Hematopoiesis / physiology. Hematopoietic Stem Cells / physiology. Histone-Lysine N-Methyltransferase. Humans. Oncogene Proteins, Fusion / physiology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Nov 15;100(10):3710-8 [12393701.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2797-802 [10688900.001]
  • [Cites] Mol Cell. 2000 May;5(5):811-20 [10882117.001]
  • [Cites] Blood. 2003 Jan 15;101(2):508-16 [12393529.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3887-93 [11090074.001]
  • [Cites] Exp Hematol. 2002 Jan;30(1):49-57 [11823037.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):161-71 [12620410.001]
  • [Cites] Leukemia. 1995 Dec;9(12):2023-6 [8609712.001]
  • [Cites] Adv Cancer Res. 2003;88:53-99 [12665053.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10984-9 [10995463.001]
  • [Cites] EMBO J. 2000 Sep 1;19(17 ):4655-64 [10970858.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):99-110 [12957285.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):88-91 [10615135.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8443-8 [15155899.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13176-81 [9789061.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3679-87 [15226186.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):173-83 [12620411.001]
  • [Cites] Cell. 1992 Nov 13;71(4):691-700 [1423624.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1064-71 [14990976.001]
  • [Cites] Leukemia. 1996 Feb;10(2):372-7 [8637251.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(8):2942-52 [12665591.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8639-48 [15378024.001]
  • [Cites] Blood. 1986 Jan;67(1):1-11 [3079640.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(1):224-34 [11113197.001]
  • [Cites] Dev Cell. 2004 Mar;6(3):437-43 [15030765.001]
  • [Cites] Stem Cells. 2002;20(5):364-79 [12351808.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Apr;39(4):335-40 [14978794.001]
  • [Cites] Cancer Causes Control. 1996 Nov;7(6):581-90 [8932918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):757-62 [14718661.001]
  • [Cites] Oncogene. 1997 Jul 31;15(5):549-60 [9247308.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3229-35 [12515728.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10735-9 [1720549.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):137-47 [12110174.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7164-77 [15378077.001]
  • [Cites] Mol Cell Biol. 1996 Jul;16(7):3308-16 [8668146.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1179-83 [8640793.001]
  • [Cites] Nat Genet. 1992 Oct;2(2):113-8 [1303259.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Apr;33(4):331-45 [11921269.001]
  • [Cites] Blood. 2003 May 1;101(9):3622-7 [12511424.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):275-85 [15050919.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):63-74 [12086889.001]
  • [Cites] Cancer Res. 1991 Dec 15;51(24):6712-4 [1835902.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1442-9 [15735032.001]
  • [Cites] Gene. 2002 Feb 6;284(1-2):73-81 [11891048.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 2003 Sep;88(5):F436-7 [12937054.001]
  • [Cites] Int J Hematol. 2003 Dec;78(5):390-401 [14704031.001]
  • [Cites] Cell. 2003 Oct 31;115(3):293-303 [14636557.001]
  • [Cites] Cancer Genet Cytogenet. 1983 Jun;9(2):139-44 [6573948.001]
  • [Cites] Blood. 2003 Jul 1;102(1):262-8 [12637319.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1107-17 [12453418.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3192-9 [15070702.001]
  • [Cites] Oncogene. 1997 Aug 18;15(8):899-910 [9285685.001]
  • [Cites] Cytogenet Cell Genet. 2000;91(1-4):52-6 [11173830.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] EMBO J. 2000 Mar 1;19(5):843-51 [10698926.001]
  • [Cites] Blood. 1998 Jul 1;92(1):108-17 [9639506.001]
  • [Cites] EMBO J. 1997 Jul 16;16(14):4226-37 [9250666.001]
  • [Cites] Oncogene. 1993 Nov;8(11):3161-4 [8414519.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1119-28 [12453419.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1445-53 [14551139.001]
  • [Cites] Blood. 2000 Jul 1;96(1):24-33 [10891426.001]
  • [Cites] Leukemia. 2003 Feb;17(2):359-65 [12592336.001]
  • [Cites] Genes Dev. 2003 Sep 15;17(18):2298-307 [12952893.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4882-7 [12941810.001]
  • [Cites] EMBO J. 1999 Jul 1;18(13):3564-74 [10393173.001]
  • [Cites] Leukemia. 1998 May;12(5):805-10 [9593285.001]
  • [Cites] Blood. 2003 Jan 15;101(2):633-9 [12393557.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):368-80 [11071359.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4849-54 [12101424.001]
  • [Cites] Nat Genet. 1997 Jul;16(3):256-9 [9207790.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(18):6542-52 [12192052.001]
  • [Cites] Lancet. 1997 Feb 1;349(9048):344-9 [9024390.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):749-54 [15640349.001]
  • [Cites] Oncogene. 1997 Oct 2;15(14 ):1681-7 [9349501.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):4070-9 [9199342.001]
  • [Cites] Nature. 1994 Jun 30;369(6483):761-6 [8008071.001]
  • [Cites] Blood. 1999 May 15;93(10):3216-24 [10233872.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):958-65 [11842107.001]
  • [Cites] Oncogene. 2003 Jan 9;22(1):157-60 [12527918.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(13):5639-49 [15199122.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2542-6 [11289128.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(2):617-28 [14701735.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(16):5678-87 [11463848.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2649-58 [8639880.001]
  • [Cites] Nature. 1992 Apr 16;356(6370):612-5 [1348572.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(7):2249-58 [11259575.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3099-104 [11867746.001]
  • [Cites] Cancer Cell. 2003 May;3(5):449-58 [12781363.001]
  • [Cites] Trends Biochem Sci. 2002 Jul;27(7):352-60 [12114024.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):197-207 [14522254.001]
  • [Cites] Curr Biol. 2004 Nov 23;14(22):2063-9 [15556871.001]
  • [Cites] EMBO J. 1998 Jul 1;17(13):3714-25 [9649441.001]
  • [Cites] EMBO J. 2005 Jan 26;24(2):368-81 [15635450.001]
  • [Cites] Cell. 1992 Nov 13;71(4):701-8 [1423625.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10398-403 [11526243.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4590-3 [12393620.001]
  • [Cites] Genomics. 1999 Jul 15;59(2):187-92 [10409430.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4584-8 [9539781.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8756-61 [11438682.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10610-4 [7938000.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23 (12 ):4230-46 [12773566.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7853-8 [12782787.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1057-62 [10419898.001]
  • [Cites] Oncogene. 1999 Dec 23;18(56):7975-84 [10637508.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31590-5 [11406628.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10 ):7050-60 [10490642.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4095-9 [10463613.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2814-9 [10706619.001]
  • [Cites] EMBO J. 2002 Aug 15;21(16):4297-306 [12169632.001]
  • [Cites] Science. 1996 Mar 29;271(5257):1873-6 [8596958.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):186-94 [12482972.001]
  • [Cites] Int J Hematol. 2002 Jul;76(1):74-9 [12138900.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1085-8 [14504097.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1823-8 [14615372.001]
  • [Cites] Blood. 2002 Jan 1;99(1):275-81 [11756182.001]
  • [Cites] Mol Cell. 2004 Feb 27;13(4):587-97 [14992727.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14 ):8342-7 [12829790.001]
  • [Cites] Mol Cell Biol. 1998 Jan;18(1):122-9 [9418860.001]
  • [Cites] Cell. 1996 Jun 14;85(6):853-61 [8681380.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):144-6 [10508507.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5695-707 [11607819.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3589-97 [11313484.001]
  • [Cites] Blood. 2004 May 15;103(10):3876-82 [14751928.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1799-806 [9292512.001]
  • [Cites] Development. 2000 Feb;127(3):643-53 [10631184.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10632-6 [9724755.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Jun;88(2):103-9 [8640717.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):134-9 [15623562.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;211:259-68 [8585957.001]
  • [Cites] Semin Hematol. 2002 Oct;39(4 Suppl 3):6-11 [12447846.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):149-53 [8563752.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3385-94 [15077184.001]
  • [Cites] Leukemia. 1998 May;12(5):811-22 [9593286.001]
  • [Cites] Nucleic Acids Res. 1998 Oct 1;26(19):4413-21 [9742243.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7286-91 [9207083.001]
  • [Cites] FASEB J. 2004 Jan;18(1):173-5 [14630694.001]
  • [Cites] Genes Dev. 1997 Mar 15;11(6):774-85 [9087431.001]
  • [Cites] Trends Mol Med. 2002 Sep;8(9):436-42 [12223315.001]
  • [Cites] Cancer Detect Prev. 2001;25(5):454-69 [11718452.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Nature. 1994 Nov 10;372(6502):143-9 [7969446.001]
  • [Cites] Nature. 1995 Nov 30;378(6556):505-8 [7477409.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5763-77 [11607826.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] Nature. 1993 May 27;363(6427):358-60 [8497319.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):539-42 [9827932.001]
  • [Cites] Oncogene. 2000 Mar 30;19(14):1744-51 [10777208.001]
  • [Cites] Semin Hematol. 1999 Oct;36(4 Suppl 7):59-72 [10595755.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):614-26 [10468849.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):639-49 [12951583.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1341-50 [15359631.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3029-35 [14701873.001]
  • [Cites] Blood. 2002 May 15;99(10):3780-5 [11986236.001]
  • [Cites] Cell. 1998 Jul 10;94(1):9-12 [9674421.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(23):10470-8 [15542854.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55 [9748598.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2124-31 [15528316.001]
  • (PMID = 16105754.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 165
  •  go-up   go-down


92. Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H, Cortes J: Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood; 2010 Jul 1;115(26):5428-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fusion Proteins, bcr-abl / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Mutation / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein Kinase Inhibitors / therapeutic use


93. Karremann M, Schreiner U, Büsing KA, von Komorowski G, Dürken M: [Acute lymphoblastic leukemia presenting without peripheral blasts but with osteolysis and hypercalcemia in an adolescent. Atypical but not rare]. Orthopade; 2009 Aug;38(8):752-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia presenting without peripheral blasts but with osteolysis and hypercalcemia in an adolescent. Atypical but not rare].
  • Joint pain is one of the major symptoms in early leukemia.
  • Acute lymphoblastic leukemia was diagnosed, but the laboratory workup and radiologic imaging revealed atypical results.
  • Particularly in early precursor B-cell acute lymphoblastic leukemia, comparable initial symptoms and signs have been reported in adolescents; therefore, we recommend performing a bone marrow aspiration early on in cases of suspected osteolytic bone lesions.
  • [MeSH-major] Hypercalcemia / complications. Hypercalcemia / diagnosis. Osteolysis / complications. Osteolysis / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Blast Crisis / complications. Blast Crisis / diagnosis. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2007 Oct;139(1):2 [17711516.001]
  • [Cites] J Pediatr Orthop. 2008 Jan-Feb;28(1):20-8 [18157042.001]
  • [Cites] J Pediatr Orthop B. 2005 May;14 (3):156-61 [15812284.001]
  • [Cites] Leukemia. 2007 Feb;21(2):288-96 [17183364.001]
  • [Cites] Pediatr Radiol. 1990;20(3):179-83 [2352796.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):990-3 [16496289.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1846-8 [11100075.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jul;43(1):66-9 [15170892.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):256-60 [8508415.001]
  • [Cites] Postgrad Med J. 1993 Jun;69(812):483-5 [8208650.001]
  • (PMID = 19533085.001).
  • [ISSN] 1433-0431
  • [Journal-full-title] Der Orthopade
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Mueller RS, Fettman MJ, Richardson K, Hansen RA, Miller A, Magowitz J, Ogilvie GK: Plasma and skin concentrations of polyunsaturated fatty acids before and after supplementation with n-3 fatty acids in dogs with atopic dermatitis. Am J Vet Res; 2005 May;66(5):868-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical scores and plasma and cutaneous concentrations of linoleic acid, arachidonic acid, alpha-linolenic acid (alpha-LLA), EPA, DHA, prostaglandin E2, and leukotriene B4 were determined.
  • RESULTS: Total plasma concentrations of alpha-LLA and EPA increased and those of arachidonic acid decreased significantly with administration of EPA-DHA, and concentrations of alpha-LLA increased with flaxseed oil supplementation; nevertheless, there was no significant change in the concentrations of these fatty acids or eicosanoids in the skin.

  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15934614.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids, Unsaturated
  •  go-up   go-down


95. Nachman JB: My aching bones: skeletal complications of acute lymphoblastic leukemia. Pediatr Blood Cancer; 2006 Jan;46(1):1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] My aching bones: skeletal complications of acute lymphoblastic leukemia.
  • [MeSH-major] Bone Diseases, Metabolic / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Blood Cancer. 2006 Jan;46(1):77-87 [16106430.001]
  • (PMID = 16261585.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Forman SJ: Role of reduced intensity transplant in adult patients with acute lymphoblastic leukemia: If and when? Best Pract Res Clin Haematol; 2009 Dec;22(4):557-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of reduced intensity transplant in adult patients with acute lymphoblastic leukemia: If and when?
  • Although allogeneic transplantation is a potentially curative therapy for adults with acute lymphoblastic leukemia (ALL), the high risk of the ablative regimen limits its use, especially in older patients where the need for better therapy is greatest.
  • Recent observations suggesting that a donor derived graft vs leukemia effect is important is facilitating cure after an allogeneic transplant has kindled interest in utilizing a reduced-intensity approach, which relies in large part on this effect to control and cure the disease.
  • Several trials have now been reported that suggest that a reduced-intensity conditioning (RIC) approach might be very effective, especially in patients who are in the first remission of the disease from either related, unrelated, or cord blood transplant donors, with approximately 50% of patients alive and in remission two years after transplant.
  • These studies suggest that prospective studies of RIC should be conducted in patients with ALL in first remission who are at high risk for relapse based on age or comorbidity to determine its role in the overall management of adult patients with this disease.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2008 Feb;93(2):303-6 [18245655.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(6):535-9 [17618317.001]
  • [Cites] Blood. 2008 Aug 1;112(3):903-9 [18519812.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):7-10 [19147069.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):11-6 [19147070.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2902-5 [19179301.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Nov;15(11):1407-14 [19822300.001]
  • [Cites] Leukemia. 2009 Oct;23(10):1763-70 [19440217.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1619-28 [7632972.001]
  • [Cites] Leukemia. 1997 May;11 Suppl 4:S15-7 [9179275.001]
  • [Cites] Bone Marrow Transplant. 1998 Jan;21(2):153-8 [9489632.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):591-8 [9718378.001]
  • [Cites] Eur J Haematol. 2005 Feb;74(2):144-51 [15654906.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1572-7 [11238093.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1094-104 [11844835.001]
  • [Cites] Leukemia. 2002 Dec;16(12):2423-8 [12454748.001]
  • [Cites] Bone Marrow Transplant. 2003 May;31(10):909-18 [12748668.001]
  • [Cites] Exp Hematol. 2003 Oct;31(10):981-6 [14550815.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Mar;10(3):195-203 [14993885.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Transplantation. 1987 Mar;43(3):389-92 [3547796.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):227-31 [3276822.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Bone Marrow Transplant. 1991 Jun;7(6):453-9 [1873592.001]
  • [Cites] Blood. 1991 Oct 15;78(8):1923-7 [1912575.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2580-7 [7989932.001]
  • [Cites] Bone Marrow Transplant. 1994 Sep;14(3):383-8 [7994259.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Sep;13(9):1083-94 [17697971.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • (PMID = 19959108.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 30206; United States / NHLBI NIH HHS / HL / U10 HL069278; United States / NCI NIH HHS / CA / CA 33572; United States / NCI NIH HHS / CA / U10 CA 46368; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / P01 CA030206
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 35
  • [Other-IDs] NLM/ NIHMS422790; NLM/ PMC3776576
  •  go-up   go-down


97. Rungoe C, Malchau EL, Larsen LN, Schroeder H: Infections during induction therapy for children with acute lymphoblastic leukemia. the role of sulfamethoxazole-trimethoprim (SMX-TMP) prophylaxis. Pediatr Blood Cancer; 2010 Aug;55(2):304-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.</